


**CUMULATIVE
SUPPLEMENT 6
JUNE 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 6

June 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 6
June 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823		
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)		
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)		
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)		
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	20	12	6		
NUMBER OF APPLICANTS	866	873	889		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM
AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE
@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
PHRENILIN FORTE
@ VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC
TABLET;ORAL
BUTAPAP
@ MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
ESGIC-PLUS
@ MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC
TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC
@ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
@ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC
@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC
ESGIC-PLUS
@ MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
PHRENILIN WITH CAFFEINE AND CODEINE
@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
@ MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC
@ PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC
AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN
@ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC
TABLET;ORAL
ANEXSIA
@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC
@ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC
ANEXSIA 7.5/650
@ MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987 Jan DISC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ AMNEAL PHARMS NY 500MG;5MG A040729 001 Aug 25, 2006 Apr DISC
@ 500MG;7.5MG A040748 001 Aug 25, 2006 Apr DISC
@ 500MG;10MG A040813 001 Feb 23, 2007 Apr DISC
@ 650MG;7.5MG A040754 001 Aug 25, 2006 Apr DISC
@ 650MG;10MG A040757 001 Aug 25, 2006 Apr DISC
@ 750MG;7.5MG A040769 001 Aug 28, 2006 Apr DISC
>D> AA CARACO 325MG;5MG A090118 001 Dec 23, 2008 Jun CAHN
>D> AA 325MG;7.5MG A090118 002 Dec 23, 2008 Jun CAHN
>D> AA 325MG;10MG A090118 003 Dec 23, 2008 Jun CAHN
@ 500MG;5MG A090265 001 Dec 23, 2008 Apr DISC
@ 500MG;7.5MG A090265 002 Dec 23, 2008 Apr DISC
@ 500MG;10MG A090265 003 Dec 23, 2008 Apr DISC
@ 650MG;7.5MG A090380 001 Dec 23, 2008 Apr DISC
@ 650MG;10MG A090380 002 Dec 23, 2008 Apr DISC
@ 660MG;10MG A090380 003 Dec 23, 2008 Apr DISC
@ 750MG;7.5MG A090380 004 Dec 23, 2008 Apr DISC
@ MALLINCKRODT 500MG;5MG A040084 002 Jun 01, 1995 Jan DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@		500MG;7.5MG	A040201	001	Feb 27, 1998	Jan	DISC
	@		500MG;10MG	A040201	002	Feb 27, 1998	Jan	DISC
	@		650MG;10MG	A040084	004	Oct 16, 1996	Jan	DISC
	@		660MG;10MG	A040084	003	Jul 29, 1996	Jan	DISC
	@		750MG;7.5MG	A040084	001	Jun 01, 1995	Jan	DISC
	@	MIKART	500MG;7.5MG	A089699	001	Aug 25, 1989	Apr	DISC
	@		650MG;7.5MG	A089689	001	Jun 29, 1988	Apr	DISC
	@		650MG;10MG	A081223	001	May 29, 1992	Apr	DISC
>A>	AA	SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008	Jun	CAHN
>A>	AA		325MG;7.5MG	A090118	002	Dec 23, 2008	Jun	CAHN
>A>	AA		325MG;10MG	A090118	003	Dec 23, 2008	Jun	CAHN
	AA	VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CAHN
	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN
	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CAHN
	@		500MG;2.5MG	A040144	002	Apr 25, 1997	Apr	DISC
	@		500MG;5MG	A089971	001	Dec 02, 1988	Apr	DISC
	@		500MG;7.5MG	A040144	001	Feb 22, 1996	Apr	DISC
	@		500MG;10MG	A040356	001	May 31, 2000	Apr	DISC
	@		650MG;7.5MG	A040155	001	Apr 14, 1997	Jan	DISC
	@		650MG;10MG	A040143	001	Feb 22, 1996	Apr	DISC
	@		660MG;10MG	A040358	001	May 31, 2000	Apr	DISC
	@		750MG;7.5MG	A040157	001	Apr 12, 1996	Jan	DISC
	@	WATSON LABS	500MG;2.5MG	A081079	001	Aug 30, 1991	Apr	DISC
	@		500MG;5MG	A089883	001	Dec 01, 1988	Apr	DISC
	@		500MG;7.5MG	A081080	001	Jan 30, 1991	Jan	DISC
	@		650MG;7.5MG	A040094	001	Sep 29, 1995	Apr	DISC
	@		650MG;10MG	A040094	002	Sep 29, 1995	Apr	DISC
	@		660MG;10MG	A040094	003	Aug 08, 2000	Apr	DISC
	@		750MG;7.5MG	A081083	001	Aug 30, 1991	Jan	DISC
	@		750MG;10MG	A040094	004	Mar 22, 1999	Apr	DISC
	@	WATSON LABS FLORIDA	660MG;10MG	A040495	001	May 28, 2003	Apr	DISC
		LORTAB						
	@	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Apr	DISC
	@		500MG;10MG	A040100	001	Jan 26, 1996	Apr	DISC
		ZYDONE						
	@	VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998	Apr	DISC
	@		400MG;7.5MG	A040288	002	Nov 27, 1998	Apr	DISC
	@		400MG;10MG	A040288	003	Nov 27, 1998	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE AND ACETAMINOPHEN

	@	DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999	Apr	DISC
	@	MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998	Jan	DISC
	@	VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996	Apr	DISC
	@	WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997	Jan	DISC
		ROXILOX						
	@	ROXANE	500MG;5MG	A040061	001	Jul 03, 1995	Apr	DISC
		TYLOX						
	@	JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984	Apr	DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	@	AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007	Apr	DISC
	@		650MG;10MG	A040789	002	Nov 27, 2007	Apr	DISC
	@	COASTAL PHARMS	500MG;7.5MG	A090177	005	Oct 20, 2008	Apr	DISC
	@		650MG;10MG	A090177	006	Oct 20, 2008	Apr	DISC
	@	MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004	Apr	DISC
	@		650MG;10MG	A040550	002	Jun 30, 2004	Apr	DISC
	@	MIKART	400MG;5MG	A040687	001	Apr 27, 2006	Apr	DISC
	@		400MG;7.5MG	A040698	001	Apr 27, 2006	Apr	DISC
	@		400MG;10MG	A040692	001	Apr 27, 2006	Apr	DISC
	@		500MG;10MG	A040676	001	Apr 19, 2006	Apr	DISC
	@	WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
	@		650MG;10MG	A040371	002	Dec 29, 2000	Jan	DISC
		PERCOCET						
	@	VINTAGE PHARMS LLC	500MG;7.5MG	A040341	001	Jul 26, 1999	Jan	DISC
	@		650MG;10MG	A040341	002	Jul 26, 1999	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

+		MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014	Mar	NEWA
---	--	------------------	-------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

@ GAVIS PHARMS 650MG;EQ 25MG BASE

A 076202 001 Aug 02, 2002 Apr DISC

@ WATSON LABS 650MG;EQ 25MG BASE

A 074699 001 Mar 24, 2000 Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB ALLIED PHARMA INC 325MG;37.5MG

A 202076 001 Mar 30, 2012 Apr CAHN

AB APOTEX INC 325MG;37.5MG

A 078778 001 Apr 07, 2014 Mar NEWA

@ WATSON LABS 325MG;37.5MG

A 076914 001 Jul 26, 2006 May DISC

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@ WATSON LABS 250MG

A 071893 001 Nov 25, 1987 May DISC

@ 500MG

A 071894 001 Nov 25, 1987 May DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

>D> AN BEDFORD 10%

A 072323 001 Apr 30, 1992 Jun CAHN

>D> AN 20%

A 072324 001 Apr 30, 1992 Jun CAHN

AN INNOPHARMA LICENSING 10%

A 204674 001 Feb 11, 2014 Jan NEWA

>A> AN ROXANE 10%

A 072323 001 Apr 30, 1992 Jun CAHN

>A> AN 20%

A 072324 001 Apr 30, 1992 Jun CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG;60MG

N 019806 001 Mar 25, 1994 Apr CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB CADILA PHARMS LTD 200MG

A 201445 001 Mar 06, 2014 Feb NEWA

ZOVIRAX

>A> AB + DELCOR ASSET 200MG

N 018828 001 Jan 25, 1985 Jun CAHN

>D> AB + GLAXOSMITHKLINE 200MG

N 018828 001 Jan 25, 1985 Jun CAHN

OINTMENT; TOPICAL

ACYCLOVIR

>A> AB AMNEAL PHARMS 5%

A 204605 001 Jun 18, 2014 Jun NEWA

TABLET; BUCCAL

SITAVIG

+ INNOCUTIS HOLDINGS 50MG

N 203791 001 Apr 12, 2013 Apr CMFD

+ 50MG

N 203791 001 Apr 12, 2013 Apr CAHN

TABLET; ORAL

ZOVIRAX

>A> AB DELCOR ASSET 400MG

N 020089 001 Apr 30, 1991 Jun CAHN

>A> AB + 800MG

N 020089 002 Apr 30, 1991 Jun CAHN

>D> AB GLAXOSMITHKLINE 400MG

N 020089 001 Apr 30, 1991 Jun CAHN

>D> AB + 800MG

N 020089 002 Apr 30, 1991 Jun CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

+ BEDFORD EQ 1GM BASE/VIAL

A 074596 001 Apr 22, 1997 Feb CRLD

@ HIKMA MAPLE EQ 1GM BASE/VIAL

A 074913 002 Oct 15, 1997 Feb DISC

@ EQ 500MG BASE/VIAL

A 074913 001 Oct 15, 1997 Feb DISC

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP AGILA SPECLTS 3MG/ML

A 078640 001 Mar 21, 2014 Mar NEWA

AP 3MG/ML

A 078686 001 May 13, 2009 Feb CAHN

AP HOSPIRA INC 3MG/ML

A 203883 001 Mar 24, 2014 Mar NEWA

AP SAGENT STRIDES 3MG/ML

A 090212 001 Mar 28, 2014 Mar NEWA

ALBUTEROL SULFATESOLUTION; INHALATION
ACCUNEB

AN	+	MYLAN SPECLT	EQ 0.021% BASE	N020949	002	Apr 30, 2001	May	CAHN
AN	+		EQ 0.042% BASE	N020949	001	Apr 30, 2001	May	CAHN

TABLET; ORAL

ALBUTEROL SULFATE

@ WATSON LABS

EQ 2MG BASE

A072764 001 Aug 28, 1991 May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATION
DUONEB

AN	+	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	May	CAHN
----	---	--------------	------------------------	---------	-----	--------------	-----	------

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

@ NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009 May DISC

@

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009 May DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb	CAHN
AB			0.5MG	A090248	002	Sep 17, 2010	Feb	CAHN
AB			1MG	A090248	003	Sep 17, 2010	Feb	CAHN
AB			2MG	A090248	004	Sep 17, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan	CAHN
		@	0.5MG	A077979	001	Feb 28, 2007	Jan	CAHN
AB			1MG	A077725	002	Jul 31, 2006	Jan	CAHN
		@	1MG	A077979	002	Feb 28, 2007	Jan	CAHN
AB			2MG	A077725	004	Jul 31, 2006	Jan	CAHN
		@	2MG	A077979	003	Feb 28, 2007	Jan	CAHN
AB			3MG	A077725	003	Jul 31, 2006	Jan	CAHN
		@	3MG	A077979	004	Feb 28, 2007	Jan	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

		@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP			0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP			0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb	CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb	CRLD

>D> AMBENONIUM CHLORIDE

>D> TABLET; ORAL

>D> MYTELEASE

>D>	+	SANOFI AVENTIS US	10MG	N010155	002		Jun	DISC
>A>		@	10MG	N010155	002		Jun	DISC

>D> AMINOHIPPURATE SODIUM

>D> INJECTABLE; INJECTION

>D> AMINOHIPPURATE SODIUM

>D>	+	MERCK	20%	N005619	001		Jun	DISC
>A>		@	20%	N005619	001		Jun	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
 AMIODARONE HYDROCHLORIDE
 @ PAR STERILE PRODUCTS 50MG/ML

A 076394 001 Apr 25, 2003 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
 AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	MUTUAL PHARM	10MG	A 089399	002	Jul 14, 1987	Jun CMS1
>A>	AB		50MG	A 089399	003	Jul 14, 1987	Jun CMS1
>A>	AB		75MG	A 089399	004	Jul 14, 1987	Jun CMS1
>A>	AB		100MG	A 089399	005	Jul 14, 1987	Jun CMS1
>A>	AB		100MG	A 089399	006	Jul 14, 1987	Jun CMS1

AMITRIPTYLINE HYDROCHLORIDE

AB	AB	ACCORD HLTHCARE	10MG	A 202446	001	Jun 04, 2014	May NEWA
AB	AB		25MG	A 202446	002	Jun 04, 2014	May NEWA
AB	AB		50MG	A 202446	003	Jun 04, 2014	May NEWA
AB	AB		75MG	A 202446	004	Jun 04, 2014	May NEWA
AB	AB		100MG	A 202446	005	Jun 04, 2014	May NEWA
AB	AB		150MG	A 202446	006	Jun 04, 2014	May NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
 AMLODIPINE BESYLATE

		@ PURACAP PHARM	EQ 2.5MG BASE	A 078131	001	Sep 04, 2007	Feb DISC
		@	EQ 5MG BASE	A 078131	002	Sep 04, 2007	Feb DISC
		@	EQ 10MG BASE	A 078131	003	Sep 04, 2007	Feb DISC
AB	AB	VIVIMED LABS	EQ 2.5MG BASE	A 077516	001	Jul 11, 2007	Apr CAHN
AB	AB		EQ 5MG BASE	A 077516	002	Jul 11, 2007	Apr CAHN
AB	AB		EQ 10MG BASE	A 077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A 203874	001	Mar 07, 2014	Feb NEWA
AB	AB		EQ 2.5MG BASE;EQ 20MG BASE	A 203874	002	Mar 07, 2014	Feb NEWA
AB	AB		EQ 2.5MG BASE;EQ 40MG BASE	A 203874	003	Mar 07, 2014	Feb NEWA
AB	AB		EQ 5MG BASE;EQ 10MG BASE	A 203874	004	Mar 07, 2014	Feb NEWA
AB	AB		EQ 5MG BASE;EQ 20MG BASE	A 203874	005	Mar 07, 2014	Feb NEWA
AB	AB		EQ 5MG BASE;EQ 40MG BASE	A 203874	006	Mar 07, 2014	Feb NEWA
AB	AB		EQ 5MG BASE;EQ 80MG BASE	A 203874	007	Mar 07, 2014	Feb NEWA
AB	AB		EQ 10MG BASE;EQ 10MG BASE	A 203874	008	Mar 07, 2014	Feb NEWA
AB	AB		EQ 10MG BASE;EQ 20MG BASE	A 203874	009	Mar 07, 2014	Feb NEWA
AB	AB		EQ 10MG BASE;EQ 40MG BASE	A 203874	010	Mar 07, 2014	Feb NEWA
AB	AB		EQ 10MG BASE;EQ 80MG BASE	A 203874	011	Mar 07, 2014	Feb NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS
 AMMONIA N 13

AP	AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204496	001	Mar 28, 2014	Mar NEWA
>A>	AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 203933	001	Jun 27, 2014	Jun NEWA
AP	AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE; ORAL
 MOXATAG

+	PRAGMA PHARMS LLC	775MG	N 050813	001	Jan 23, 2008	Apr CAHN
---	-------------------	-------	----------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	AB	SANDOZ	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 30MG	A 202588	001	Mar 04, 2014	Feb NEWA
----	----	--------	---	----------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, N/A, 20MG	N 050824	001	Feb 08, 2011	Mar CDFR
---	--------------	---	----------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A 040456	001	May 06, 2003	Apr	CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 040456	002	May 06, 2003	Apr	CMFD
AB		5MG;5MG;5MG;5MG	A 040456	003	May 06, 2003	Apr	CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 040456	004	May 06, 2003	Apr	CMFD

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A 202198	001	Apr 07, 2014	Mar	NEWA
>D>	@ ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun	CMFD
>A>	AP	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun	CMFD
>D>	@	EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun	CMFD
>A>	AP	EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun	CMFD
>D>	@	EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun	CMFD
>A>	AP	EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun	CMFD
>D>	@	EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun	CMFD
>A>	AP	EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun	CMFD
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A 062719	002	May 12, 1987	Feb	CAHN
AP		EQ 2GM BASE/VIAL	A 062797	002	Jul 12, 1993	Feb	CAHN
AP		EQ 10GM BASE/VIAL	A 201404	001	Dec 20, 2013	Jan	CPOT
AP		EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Feb	CAHN
AP		EQ 250MG BASE/VIAL	A 062719	001	May 12, 1987	Feb	CAHN
AP		EQ 500MG BASE/VIAL	A 062719	003	May 12, 1987	Feb	CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A 201025	003	Apr 09, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A 201025	004	Apr 09, 2014	Mar	NEWA
AP		EQ 250MG BASE/VIAL	A 201025	001	Apr 09, 2014	Mar	NEWA
AP		EQ 500MG BASE/VIAL	A 201025	002	Apr 09, 2014	Mar	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 201024	001	Apr 07, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 201024	002	Apr 07, 2014	Mar	NEWA
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 202197	001	Apr 07, 2014	Mar	NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065222	001	Nov 29, 2005	Feb	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065222	002	Nov 29, 2005	Feb	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 065314	001	Nov 27, 2006	Feb	CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065316	001	Jun 29, 2007	May	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065316	002	Jun 29, 2007	May	CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@ WATSON LABS

1MG

A 078984 001 Jun 28, 2010 May DISC

APREMILAST

TABLET; ORAL

OTEZLA

CELGENE CORP

10MG

N 205437 001 Mar 21, 2014 Mar NEWA

20MG

N 205437 002 Mar 21, 2014 Mar NEWA

+

30MG

N 205437 003 Mar 21, 2014 Mar NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

>A>	AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A 202626	001	Jun 30, 2014	Jun	NEWA
>A>	AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A 091665	001	Jun 30, 2014	Jun	NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

WATSON LABS INC

200MG

A 200156 004 Aug 29, 2012 May CTEC

NUVIGIL

CEPHALON

200MG

N 021875 005 Mar 26, 2009 May CMFD

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

	FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
@ WATSON LABS

325MG;50MG;40MG;30MG

A074359 001 Aug 31, 1995 Mar DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@ STEVENS J

385MG;30MG;25MG

A074988 001 Apr 30, 1999 Mar DISC

@

770MG;60MG;50MG

A074988 002 Apr 30, 1999 Mar DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ MIRROR PHARMS

325MG;200MG;16MG

A040860 001 Jan 07, 2010 Mar DISC

@ PROSAM LABS

325MG;200MG;16MG

A040283 001 Dec 29, 1998 Mar DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ WATSON LABS

325MG;4.5MG;0.38MG

A040255 001 Feb 27, 1998 May DISC

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB TEVA PHARMS USA

EQ 100MG BASE

A091673 001 Apr 22, 2014 Apr NEWA

AB

EQ 150MG BASE

A091673 002 Apr 22, 2014 Apr NEWA

AB

EQ 200MG BASE

A091673 003 Apr 22, 2014 Apr NEWA

AB

EQ 300MG BASE

A091673 004 Apr 22, 2014 Apr NEWA

REYATAZ

AB BRISTOL MYERS SQUIBB

EQ 100MG BASE

N021567 001 Jun 20, 2003 Apr CFTG

AB

EQ 150MG BASE

N021567 002 Jun 20, 2003 Apr CFTG

AB

EQ 200MG BASE

N021567 003 Jun 20, 2003 Apr CFTG

AB

+

EQ 300MG BASE

N021567 004 Oct 16, 2006 Apr CFTG

>A>

POWDER;ORAL

>A>

REYATAZ

>A>

+

BRISTOL MYERS SQUIBB

EQ 50MG BASE/PACKET

N206352 001 Jun 02, 2014 Jun NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB

MYLAN

50MG

A073457 003 Jan 24, 1992 Apr CMS1

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB

AMNEAL PHARMS

750MG/5ML

A202960 001 Mar 18, 2014 Mar NEWA

MEPRON

AB

+

GLAXOSMITHKLINE LLC

750MG/5ML

N020500 001 Feb 08, 1995 Mar CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB

MYLAN PHARMS INC

62.5MG;25MG

A202362 001 May 27, 2014 May NEWA

AB

250MG;100MG

A202362 002 May 27, 2014 May NEWA

MALARONE PEDIATRIC

AB

GLAXOSMITHKLINE

62.5MG;25MG

N021078 002 Jul 14, 2000 May CTEC

ATROPINE SULFATE

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ HOSPIRA

0.05MG/ML

N021146 002 Jul 09, 2001 May CRLD

AZELASTINE HYDROCHLORIDE

>D>	SPRAY;NASAL							
>D>	AZELASTINE HYDROCHLORIDE							
>D>	AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Jun	CDFR
	AB		EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Apr	NEWA
>A>	SPRAY, METERED;NASAL							
>A>	AZELASTINE HYDROCHLORIDE							
>A>	AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Jun	CDFR

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

	ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb	CAHN
+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOL

	ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb	CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb	CAHN

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001			Feb	CTEC
---	----------------------	--------------	---------	-----	--	--	-----	------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB	MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Jan	CTNA
AB		5MG;80MG	A078688	002	Feb 15, 2008	Jan	CTNA

BENZONATATE

CAPSULE;ORAL

BENZONATATE

>D>	AA	CARACO	100MG	A040587	001	Mar 19, 2008	Jun	CAHN
>D>	AA		200MG	A040587	002	Mar 19, 2008	Jun	CAHN
>A>	AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Jun	CAHN
>A>	AA		200MG	A040587	002	Mar 19, 2008	Jun	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZAOLIN

AB	+	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar	CRLD
	+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar	CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPREVE

+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Apr	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

LOTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan	CAHN
----	---	-------------------	------------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

>D>	AA	CARACO	5MG	A040897	001	Apr 22, 2009	Jun	CAHN
>D>	AA		10MG	A040897	002	Apr 22, 2009	Jun	CAHN
>D>	AA		25MG	A040897	003	Apr 22, 2009	Jun	CAHN
>D>	AA		50MG	A040897	004	Apr 22, 2009	Jun	CAHN
>A>	AA	SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun	CAHN
>A>	AA		10MG	A040897	002	Apr 22, 2009	Jun	CAHN
>A>	AA		25MG	A040897	003	Apr 22, 2009	Jun	CAHN
>A>	AA		50MG	A040897	004	Apr 22, 2009	Jun	CAHN
		DUVOID						
	@	WELLSPRING PHARM	10MG	A086262	001		Mar	DISC
	@		25MG	A086263	001		Mar	DISC
	@		50MG	A085882	003		Mar	DISC

BICALUTAMIDETABLET; ORAL
BICALUTAMIDE

>D>	AB	ROXANE	50MG	A078285	001	Mar 24, 2011	Jun	DISC
>A>		@	50MG	A078285	001	Mar 24, 2011	Jun	DISC

BIMATOPROSTSOLUTION/DROPS; OPHTHALMIC
LUMIGAN

@	ALLERGAN	0.03%	N021275	001	Mar 16, 2001	May	DISC
---	----------	-------	---------	-----	--------------	-----	------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr	CAHN
+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	2.5MG; 6.25MG	A075469	001	Sep 25, 2000	May	DISC
@		5MG; 6.25MG	A075469	002	Sep 25, 2000	May	DISC
@		10MG; 6.25MG	A075469	003	Sep 25, 2000	May	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CAHN
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG

BROMFENAC SODIUM

>A>	AT1	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	NEWA
>A>	AT		EQ 0.09% ACID	A202620	001	Jun 23, 2014	Jun	NEWA
	AT1	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
	AT	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
	AT1	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC
		XIBROM						
		@ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

>D>	+	WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Jun	CTEC
>A>	AA	+	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Jun	CTEC
>A>		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
>A>	AA	PADDOCK LLC	2MG/5ML; 10MG/5ML; 30MG/5ML	A205292	001	Jul 15, 2014	Jun	NEWA

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar	NEWA
----	--	--------------------	-----	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

BUDESONIDE

AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr	NEWA
		RHINOCORT						
	+	ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr	CFTG

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb	CAHN
+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

>A>		PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Jun	NEWA
-----	--	------------------	-----------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

>A>	FILM;BUCCAL								
>A>	BUNAVAIL								
>A>	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE		N205637	001	Jun 06, 2014	Jun	NEWA	
>A>		EQ 4.2MG BASE;EQ 0.7MG BASE		N205637	002	Jun 06, 2014	Jun	NEWA	
>A>	+	EQ 6.3MG BASE;EQ 1MG BASE		N205637	003	Jun 06, 2014	Jun	NEWA	
	TABLET;SUBLINGUAL								
	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE								
>A>	AB	ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Jun	NEWA	
>A>	AB	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
>A>	AB	ROXANE	EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Jun	NEWA	

BUPROPION HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL								
	BUPROPION HYDROCHLORIDE								
AB3	ZYDUS PHARMS USA INC	300MG		A201567	001	Jan 17, 2014	Jan	NEWA	

BUSPIRONE HYDROCHLORIDE

	TABLET;ORAL								
	BUSPIRONE HYDROCHLORIDE								
AB	ZYDUS PHARMS USA INC	5MG		A078888	001	Feb 07, 2014	Jan	NEWA	
AB		10MG		A078888	002	Feb 07, 2014	Jan	NEWA	
AB		15MG		A078888	003	Feb 07, 2014	Jan	NEWA	
AB		30MG		A078888	004	Feb 07, 2014	Jan	NEWA	

BUTENAFINE HYDROCHLORIDE

	CREAM;TOPICAL								
>D>	MENTAX-TC								
>D>	+	MYLAN	1%	N021408	001	Oct 17, 2002	Jun	DISC	
>A>	@		1%	N021408	001	Oct 17, 2002	Jun	DISC	

BUTOCONAZOLE NITRATE

	CREAM;VAGINAL								
	GYNAZOLE-1								
	@ LUMARA HEALTH INC	2%		N019881	001	Feb 07, 1997	May	CAHN	

BUTORPHANOL TARTRATE

	INJECTABLE;INJECTION								
	BUTORPHANOL TARTRATE								
	@ HIKMA FARMACEUTICA	2MG/ML		A078247	001	Apr 29, 2009	May	DISC	

CAFFEINE CITRATE

	SOLUTION;INTRAVENOUS								
	CAFFEINE CITRATE								
AP	EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A077233	001	Sep 21, 2006	Feb	CAHN	
	SOLUTION;ORAL								
	CAFFEINE CITRATE								
AA	EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A077304	001	Sep 21, 2006	Feb	CAHN	

CALCIPOTRIENE

	SOLUTION;TOPICAL								
	CALCIPOTRIENE								
	@ HI TECH PHARMA	0.005%		A077579	001	Nov 19, 2009	May	DISC	
AT	+	TOLMAR	0.005%	A077029	001	Nov 20, 2009	Apr	CRLD	
	DOVONEX								
	@ LEO PHARM	0.005%		N020611	001	Mar 03, 1997	Apr	DISC	

CALCITRIOL

	INJECTABLE;INJECTION								
	CALCITRIOL								
	@ TEVA PARENTERAL	0.002MG/ML		A075823	002	Mar 31, 2003	Feb	DISC	

CAPTOPRIL

	TABLET;ORAL								
	CAPTOPRIL								
	@ DAVA PHARMS INC	12.5MG		A074423	001	Feb 13, 1996	May	CAHN	
	@	25MG		A074423	002	Feb 13, 1996	May	CAHN	
	@	50MG		A074423	003	Feb 13, 1996	May	CAHN	
	@	100MG		A074423	004	Feb 13, 1996	May	CAHN	
	@ WATSON LABS	12.5MG		A074451	001	Feb 13, 1996	Mar	DISC	

TABLET;ORAL							
CAPTOPRIL							
	@	25MG	A074451	002	Feb 13, 1996	Mar	DISC
	@	50MG	A074451	003	Feb 13, 1996	Mar	DISC
	@	100MG	A074451	004	Feb 13, 1996	Mar	DISC
<u>CAPTROPIL; HYDROCHLOROTHIAZIDE</u>							
TABLET;ORAL							
CAPOZIDE 25/15							
	@	APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC
CAPOZIDE 25/25							
	@	APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
CAPOZIDE 50/15							
	@	APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
CAPOZIDE 50/25							
	@	APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
AB	+	MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
AB	+		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD
<u>CARBIDOPA</u>							
TABLET;ORAL							
CARBIDOPA							
AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
LODOSYN							
AB	+	ATON	25MG	N017830	001		Feb CFTG
<u>CARBINOXAMINE MALEATE</u>							
SOLUTION;ORAL							
CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
TABLET;ORAL							
CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN
<u>CARBOPLATIN</u>							
INJECTABLE;INJECTION							
CARBOPLATIN							
	@	BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
	@	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
	@		150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
	@		450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
	@	FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
	@	ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC
	@		150MG/VIAL	A091510	002	May 29, 2012	May DISC
	@		450MG/VIAL	A091510	003	May 29, 2012	May DISC
	@	SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
	@		150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
	@		450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
	@	WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
	@		150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
	@		450MG/VIAL	A076162	003	Oct 14, 2004	May DISC
INJECTABLE;IV (INFUSION)							
CARBOPLATIN							
AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN
<u>CARISOPRODOL</u>							
TABLET;ORAL							
CARISOPRODOL							
AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA

CEFACLORFOR SUSPENSION; ORAL
CEFACLOR

AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan	CRLD
----	---	-----------------	-------------------	---------	-----	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

	@	ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan	CAHN
	@		EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan	CAHN
	@		EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan	CAHN
	@		EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan	CAHN
	@		EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan	CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

	@	STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar	DISC
--	---	--------------	------------------	---------	-----	--------------	-----	------

CEFTAZIDIMEINJECTABLE; INJECTION
FORTAZ

AP	+	COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May	CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	May	CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	May	CAHN
AP	+		500MG/VIAL	N050578	001	Jul 19, 1985	May	CAHN

CEFTAZIDIME SODIUMINJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

	@	COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb	CAHN
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr	NEWA

CEFUROXIME SODIUMINJECTABLE; IM-IV
ZINACEF

AB	+	COVIS INJECTABLES	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN
		INJECTABLE; INJECTION						
		ZINACEF						
AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN
		ZINACEF IN PLASTIC CONTAINER						
	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May	CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May	CAHN

CELECOXIBCAPSULE; ORAL
CELEBREX

AB		GD SEARLE	50MG	N020998	004	Dec 15, 2006	May	CFTG
AB			100MG	N020998	001	Dec 31, 1998	May	CFTG
AB			200MG	N020998	002	Dec 31, 1998	May	CFTG
AB	+		400MG	N020998	003	Aug 29, 2002	May	CFTG

CELECOXIB

AB		MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May	NEWA
AB		TEVA	50MG	A076898	001	May 30, 2014	May	NEWA
AB			100MG	A076898	002	May 30, 2014	May	NEWA
AB			200MG	A076898	003	May 30, 2014	May	NEWA
AB			400MG	A076898	004	May 30, 2014	May	NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

>D>	AB	FACTA FARMA	EQ 250MG BASE	A 062118	001		Jun	DISC
>A>		@	EQ 250MG BASE	A 062118	001		Jun	DISC
>D>	AB		EQ 500MG BASE	A 062118	002		Jun	DISC
>A>		@	EQ 500MG BASE	A 062118	002		Jun	DISC
		@ STEVENS J	EQ 250MG BASE	A 062870	001	Mar 17, 1988	Mar	DISC

FOR SUSPENSION;ORAL
CEPHALEXIN

>D>	AB	FACTA FARMA	EQ 125MG BASE/5ML	A 062117	002		Jun	DISC
>A>		@	EQ 125MG BASE/5ML	A 062117	002		Jun	DISC
>D>	AB	+	EQ 250MG BASE/5ML	A 062117	003		Jun	DISC
>A>		@	EQ 250MG BASE/5ML	A 062117	003		Jun	DISC

CERITINIBCAPSULE;ORAL
ZYKADIA

		+	NOVARTIS PHARMS CORP	150MG	N 205755	001	Apr 29, 2014	Apr	NEWA
--	--	---	----------------------	-------	----------	-----	--------------	-----	------

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB		PACK PHARMS LLC	30MG	A 203775	001	Jun 04, 2014	May	NEWA
----	--	-----------------	------	----------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE;ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

		@ WATSON LABS	5MG	A 086383	001		May	DISC
		@	10MG	A 086294	001		May	DISC
		@	25MG	A 086382	001		May	DISC

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

>A>	AP	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	A 202493	001	Jun 18, 2014	Jun	NEWA
-----	----	---------------------	--------------------	----------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A 204627	001	Apr 29, 2014	Apr	NEWA	
AA		ZUTRIPRO							
AA		+	CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N 022439	001	Jun 08, 2011	Apr	CFTG

CHLORPROPAMIDETABLET;ORAL
CHLORPROPAMIDE

		@ ANI PHARMS INC	100MG	A 088768	001	Oct 11, 1984	Jan	CAHN
		@	100MG	A 088812	001	Oct 19, 1984	Jan	CAHN
		@	100MG	A 088840	001	Oct 25, 1984	Feb	CAHN
		@	100MG	A 088918	001	Oct 16, 1984	Jan	CAHN
AB		@	100MG	A 088921	001	Apr 12, 1985	Jan	CAHN
		@	100MG	A 089446	001	Nov 17, 1986	Jan	CAHN
		@	250MG	A 088813	001	Oct 19, 1984	Jan	CAHN
		@	250MG	A 088919	001	Oct 16, 1984	Jan	CAHN
AB		@	250MG	A 088922	001	Apr 12, 1985	Jan	CAHN
		@	250MG	A 089447	001	Nov 17, 1986	Jan	CAHN
		@ TEVA PHARMS USA	250MG	A 087353	001		Apr	CAHN
		GLUCAMIDE						
		@ ANI PHARMS INC	250MG	A 088641	001	Oct 11, 1984	Jan	CAHN
		@ TEVA PHARMS USA	250MG	A 088641	001	Oct 11, 1984	Apr	CAHN

CHLORZOXAZONETABLET;ORAL
CHLORZOXAZONE

>A>		@ ACTAVIS ELIZABETH	250MG	A 088928	001	May 08, 1987	Jun	CAHN
>D>		@ ACTAVIS TOTOWA	250MG	A 088928	001	May 08, 1987	Jun	CAHN
		@ WATSON LABS	500MG	A 040137	001	Aug 09, 1996	May	DISC
		@	500MG	A 081040	001	Aug 22, 1989	May	DISC

CICLOPIROXCREAM; TOPICAL
CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb	DISC

CIMETIDINE HYDROCHLORIDESOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN

CIPROFLOXACINFOR SUSPENSION; ORAL
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
	CIPROFLOXACIN						
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT	WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN
----	-----------------	--------------	---------	-----	--------------	-----	------

CISPLATININJECTABLE; INJECTION
CISPLATIN

AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDETABLET; ORAL
CITALOPRAM HYDROBROMIDE

	@ WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005	May	DISC
	@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May	DISC
	@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATECREAM; VAGINAL
CLINDESSE

	+	LUMARA HEALTH INC	EQ 2% BASE	N050793	001	Nov 30, 2004	May	CAHN
--	---	-------------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD	
>D>	AB	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun	CTEC
>A>	AT		EQ 1% BASE	A062811	001	Sep 01, 1988	Jun	CTEC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN	
	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN	

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL
OLUX

>A>	AB1	+	DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun	CAHN
>D>	AB1	+	STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	Jun	CAHN

CLONIDINEFILM, EXTENDED RELEASE; TRANSDERMAL
CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr	NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr	NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	CARACO	0.1MG	A090329	001	Jul 03, 2014	Jun	NEWA
>A>	AB		0.2MG	A090329	002	Jul 03, 2014	Jun	NEWA
>A>	AB		0.3MG	A090329	003	Jul 03, 2014	Jun	NEWA
		@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May	DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA

CLOPIDOGREL

TABLET; ORAL

CLOPIDOGREL

AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
----	---------------	------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ WATSON LABS

3.75MG

A071852 001 Feb 09, 1988 May DISC

@

7.5MG

A071853 001 Feb 09, 1988 May DISC

@

15MG

A071854 001 Feb 09, 1988 May DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

>A>	AB	LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun	NEWA
>A>	AB		30MG	A203046	002	Jun 13, 2014	Jun	NEWA
>A>	AB		60MG	A203046	003	Jun 13, 2014	Jun	NEWA
>D>	AB	ROXANE	15MG	N022402	001	Jul 16, 2009	Jun	CFTG
>A>	AB		15MG	N022402	001	Jul 16, 2009	Jun	CFTG
>D>	AB		30MG	N022402	002	Jul 16, 2009	Jun	CFTG
>A>	AB		30MG	N022402	002	Jul 16, 2009	Jun	CFTG
>D>	+		60MG	N022402	003	Jul 16, 2009	Jun	CFTG
>A>	AB	+	60MG	N022402	003	Jul 16, 2009	Jun	CFTG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA
AP	+ PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr	CAHN
---	----------------------	---	---------	-----	--	-----	------

CONIVAPTAN HYDROCHLORIDEINJECTABLE; IV (INFUSION)
VAPRISOL

@ CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb CAHN
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER					
+ CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb CAHN

CROMOLYN SODIUMSOLUTION; INHALATION
CROMOLYN SODIUM

AN	MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May CAHN
	@ WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May DISC
	SOLUTION/DROPS; OPHTHALMIC					
	CROMOLYN SODIUM					
>D> AT	AKORN	4%	A074706	001	Apr 29, 1998	Jun CRLD
>A> AT	+	4%	A074706	001	Apr 29, 1998	Jun CRLD
>D>	OPTICROM					
>D> AT	+ ALLERGAN	4%	N018155	001	Oct 03, 1984	Jun DISC
>A>	@	4%	N018155	001	Oct 03, 1984	Jun DISC

DALBAVANCIN HYDROCHLORIDEINJECTABLE; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May NEWA
-----------------------	--------------------	---------	-----	--------------	----------

DANTROLENE SODIUMCAPSULE; ORAL
DANTRIUM

AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar CAHN
AB		50MG	N017443	003		Mar CAHN
AB	+	100MG	N017443	002		Mar CAHN
	INJECTABLE; INJECTION					
	DANTRIUM					
AP	+ PAR STERILE PRODUCTS	20MG/VIAL	N018264	001		Apr CAHN
	REVONTO					
AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar CTNA

DAPAGLIFLOZINTABLET; ORAL
FARXIGA

ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CAHN
+	10MG	N202293	002	Jan 08, 2014	Feb CAHN
BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan NEWA
+	10MG	N202293	002	Jan 08, 2014	Jan NEWA

DECITABINEPOWDER; INTRAVENOUS
DECITABINE

+ SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan NEWA
---------------------	-----------	---------	-----	--------------	----------

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

@ WATSON LABS	2GM/VIAL	A076806	002	Mar 31, 2006	May DISC
@	500MG/VIAL	A076806	001	Mar 31, 2006	May DISC

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

@ ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan CAHN
@	50MG	A071801	001	Dec 08, 1987	Jan CAHN
@	75MG	A071802	001	Dec 08, 1987	Jan CAHN
@	100MG	A071803	001	May 29, 1997	Feb CAHN
@	150MG	A071804	001	May 29, 1997	Feb CAHN

DESLORATADINESOLUTION;ORAL
CLARINEX

+ MERCK SHARP DOHME 0.5MG/ML N021300 001 Sep 01, 2004 May CDFR

DESMOPRESSIN ACETATESPRAY, METERED;NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB SUN PHARMA GLOBAL 0.01MG/SPRAY A078271 001 Dec 23, 2013 Jan CMS2

TABLET;ORAL

DESMOPRESSIN ACETATE

>A> AB MYLAN PHARMS INC 0.1MG A200653 001 Jun 27, 2014 Jun NEWA

>A> AB 0.2MG A200653 002 Jun 27, 2014 Jun NEWA

DESONIDEAEROSOL, FOAM;TOPICAL
VERDESO

+ AQUA PHARMS 0.05% N021978 001 Sep 19, 2006 May CAHN

DESOXIMETASONEOINTMENT;TOPICAL
DESOXIMETASONE

AB VERSAPHARM INC 0.25% A201005 001 Apr 24, 2014 Apr NEWA

DESVENLAFAXINETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

BC SUN PHARMA GLOBAL 50MG N205583 001 Jan 28, 2014 Jan NEWA

BC + 100MG N205583 002 Jan 28, 2014 Jan NEWA

DESVENLAFAXINE FUMARATETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

>A> + SUN PHARMA GLOBAL EQ 50MG BASE N205583 001 Jan 28, 2014 Jun CTNA

>A> + EQ 100MG BASE N205583 002 Jan 28, 2014 Jun CTNA

>A> @ TEVA PHARMS USA EQ 50MG BASE N205208 001 Oct 11, 2013 Jun DISC

>A> + EQ 50MG BASE N205208 001 Oct 11, 2013 Jun CTNA

>A> @ EQ 100MG BASE N205208 002 Oct 11, 2013 Jun DISC

>A> + EQ 100MG BASE N205208 002 Oct 11, 2013 Jun CTNA

>D> DESVENLAFAXINE FUMARATE

>D> + SUN PHARMA GLOBAL EQ 50MG BASE N205583 001 Jan 28, 2014 Jun CTNA

+ EQ 50MG BASE N205583 001 Jan 28, 2014 Feb CTEC

>D> + EQ 100MG BASE N205583 002 Jan 28, 2014 Jun CTNA

+ EQ 100MG BASE N205583 002 Jan 28, 2014 Feb CTEC

>D> + TEVA PHARMS USA EQ 50MG BASE N205208 001 Oct 11, 2013 Jun CTNA

>D> + EQ 100MG BASE N205208 002 Oct 11, 2013 Jun CTNA

DEXCHLORPHENIRAMINE MALEATETABLET;ORAL
DEXCHLORPHENIRAMINE MALEATE

@ ANI PHARMS INC 2MG A088682 001 Jan 17, 1986 Jan CAHN

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL
DEXILANT

>D> TAKEDA PHARMS 30MG N022287 001 Jan 30, 2009 Jun CAHN

>D> + 60MG N022287 002 Jan 30, 2009 Jun CAHN

>A> TAKEDA PHARMS USA 30MG N022287 001 Jan 30, 2009 Jun CAHN

>A> + 60MG N022287 002 Jan 30, 2009 Jun CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB TEVA PHARMS USA 15MG A078908 004 May 19, 2014 May NEWA

AB 30MG A202731 003 May 19, 2014 May NEWA

AB WATSON LABS INC 15MG A079108 003 May 19, 2014 May NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	COREPHARMA	5MG	A 090652	001	Mar 07, 2014	Feb	NEWA
AA		10MG	A 090652	002	Mar 07, 2014	Feb	NEWA

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/ML	A 204433	001	Apr 14, 2014	Mar	NEWA
AA	+ DIAZEPAM INTENSOL						
AA	+ ROXANE	5MG/ML	A 071415	001	Apr 03, 1987	Mar	CFTG
	TABLET; ORAL						
	DIAZEPAM						
	@ DAVA PHARMS INC	2MG	A 070226	001	Sep 26, 1985	Mar	DISC

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL

CAMBIA

	+ DEPOMED INC	50MG	N 022165	001	Jun 17, 2009	Jan	CAHN
--	---------------	------	----------	-----	--------------	-----	------

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	APOTEX INC	1.5%	A 202027	001	May 27, 2014	May	NEWA
	PENNSAID						
AT	+ MALLINCKRODT	1.5%	N 020947	001	Nov 04, 2009	May	CFTG
	+ MALLINCKRODT INC	2%	N 204623	001	Jan 16, 2014	Jan	NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG; 0.2MG	A 200540	001	Mar 14, 2014	Mar	NEWA
AB		75MG; 0.2MG	A 200540	002	Mar 14, 2014	Mar	NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

AB	+ FOREST LABS INC	10MG	N 007409	003	Oct 15, 1984	Apr	CAHN
	INJECTABLE; INJECTION						
	BENTYL						
AP	+ FOREST LABS INC	10MG/ML	N 008370	001	Oct 15, 1984	Apr	CAHN
	BENTYL PRESERVATIVE FREE						
AP	+ FOREST LABS INC	10MG/ML	N 008370	002	Oct 15, 1984	Apr	CAHN
	TABLET; ORAL						
	BENTYL						
AB	+ FOREST LABS INC	20MG	N 007409	001	Oct 15, 1984	Apr	CAHN

DIGOXIN

INJECTABLE; INJECTION

LANOXIN

AP	+ COVIS INJECTABLES	0.25MG/ML	N 009330	002		Apr	CAHN
	LANOXIN PEDIATRIC						
	+ COVIS INJECTABLES	0.1MG/ML	N 009330	004		Apr	CAHN
	TABLET; ORAL						
	LANOXIN						
	COVIS PHARMA	0.0625MG	N 020405	001	Sep 30, 1997	Jan	CMFD
		0.1875MG	N 020405	003	Sep 30, 1997	Jan	CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

@ NESHER PHARMS

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ AGILA SPECLTS 5MG/ML

A075375 001 Sep 30, 1999 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

>D> AP INTL MEDICATION 50MG/ML

A084094 001

Jun DISC

>A> @ 50MG/ML

A084094 001

Jun DISC

>D> DIPIVEFRIN HYDROCHLORIDE

>D> SOLUTION/DROPS; OPHTHALMIC

>D> AKPRO

>D> AT AKORN 0.1%

A074382 001 Sep 29, 1995 Jun DISC

>A> @ 0.1%

A074382 001 Sep 29, 1995 Jun DISC

>D> DIPIVEFRIN HYDROCHLORIDE

>D> AT FALCON PHARMS 0.1%

A073636 001 Jun 30, 1994 Jun DISC

>A> @ 0.1%

A073636 001 Jun 30, 1994 Jun DISC

>D> PROPINE

>D> AT + ALLERGAN 0.1%

N018239 001 Jun DISC

>A> @ 0.1%

N018239 001 Jun DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ GLENMARK GENERICS 25MG

A088999 001 Feb 05, 1991 Mar DISC

@ 50MG

A089000 001 Feb 05, 1991 Mar DISC

@ 75MG

A089001 001 Feb 05, 1991 Mar DISC

@ WATSON LABS 50MG

A087160 001 Jun 07, 1996 May DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB ROXANE 250MG

A202652 001 Feb 05, 2014 Jan NEWA

AB 500MG

A202652 002 Feb 05, 2014 Jan NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB AUROBINDO PHARMA LTD EQ 250MG VALPROIC ACID

A202419 001 Jun 02, 2014 May NEWA

AB EQ 500MG VALPROIC ACID

A202419 002 Jun 02, 2014 May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

@ WATSON LABS EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993 May DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

PFIZER LABS 20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014 Mar NEWA

80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014 Mar NEWA

130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014 Mar NEWA

200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014 Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB MACLEODS PHARMS LTD 23MG

A202631 001 Jan 22, 2014 Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

@ WATSON LABS 20MG/ML

A073529 001 Jan 30, 1992 May DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB ACCORD HLTHCARE EQ 1MG BASE

A202824 001 Jun 11, 2014 May NEWA

AB EQ 2MG BASE

A202824 002 Jun 11, 2014 May NEWA

AB EQ 4MG BASE

A202824 003 Jun 11, 2014 May NEWA

AB EQ 8MG BASE

A202824 004 Jun 11, 2014 May NEWA

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP	SANDOZ	4MCG/2ML (2MCG/ML)	A 091333	001	May 05, 2014	Apr	NEWA
AP		4MCG/2ML (2MCG/ML)	A 200926	001	Feb 04, 2014	Jan	NEWA

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

>A>	AP	ACTAVIS INC	2MG/ML	A 203622	001	Jun 27, 2014	Jun	NEWA
	AP	PHARMACHEMIE BV	2MG/ML	A 063336	001	Feb 28, 1995	Feb	CAHN
	AP		10MG/VIAL	A 063097	001	May 21, 1990	Feb	CAHN
	AP		20MG/VIAL	A 063097	002	May 21, 1990	Feb	CAHN
	AP		50MG/VIAL	A 063097	003	May 21, 1990	Feb	CAHN
	AP		200MG/100ML	A 063336	004	Feb 28, 1995	Feb	CAHN

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A 204234	001	Mar 05, 2014	Feb	NEWA
AB		EQ 75MG BASE	A 204234	002	Mar 05, 2014	Feb	NEWA
AB		EQ 100MG BASE	A 204234	003	Mar 05, 2014	Feb	NEWA
	@ WATSON LABS	EQ 50MG BASE	A 065041	001	Apr 28, 2000	May	DISC
	@	EQ 100MG BASE	A 065041	002	Apr 28, 2000	May	DISC

DOXYCYCLINE HYCLATETABLET, DELAYED RELEASE; ORAL
DORYX

AB	MAYNE PHARMA	EQ 150MG BASE	N 050795	003	Jun 20, 2008	Feb	CRLD
	+	EQ 200MG BASE	N 050795	005	Apr 11, 2013	Feb	CRLD

DRONABINOLCAPSULE; ORAL
DRONABINOL

>A>	AB	AKORN INC	2.5MG	A 079217	001	Jun 20, 2014	Jun	NEWA
>A>	AB		5MG	A 079217	002	Jun 20, 2014	Jun	NEWA
>A>	AB		10MG	A 079217	003	Jun 20, 2014	Jun	NEWA

DROSPIRENONE; ETHINYL ESTRADIOLTABLET; ORAL
NIKKI

AB	LUPIN LTD	3MG; 0.02MG	A 201661	001	May 27, 2014	May	NEWA
----	-----------	-------------	----------	-----	--------------	-----	------

DROXIDOPACAPSULE; ORAL
NORTHERA

>D>		CHELSEA THERAPS INC	100MG	N 203202	001	Feb 18, 2014	Jun	CAHN
			100MG	N 203202	001	Feb 18, 2014	Feb	NEWA
>D>			200MG	N 203202	002	Feb 18, 2014	Jun	CAHN
			200MG	N 203202	002	Feb 18, 2014	Feb	NEWA
>D>	+		300MG	N 203202	003	Feb 18, 2014	Jun	CAHN
	+		300MG	N 203202	003	Feb 18, 2014	Feb	NEWA
>A>		LUNDBECK NA LTD	100MG	N 203202	001	Feb 18, 2014	Jun	CAHN
>A>			200MG	N 203202	002	Feb 18, 2014	Jun	CAHN
>A>	+		300MG	N 203202	003	Feb 18, 2014	Jun	CAHN

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A 202949	001	Jun 09, 2014	May	NEWA
AB		EQ 30MG BASE	A 202949	002	Jun 09, 2014	May	NEWA
AB		EQ 60MG BASE	A 202949	003	Jun 09, 2014	May	NEWA
AB	APOTEX INC	EQ 20MG BASE	A 202045	001	Jun 11, 2014	May	NEWA
AB		EQ 30MG BASE	A 202045	002	Jun 11, 2014	May	NEWA
AB		EQ 60MG BASE	A 202045	003	Jun 11, 2014	May	NEWA
AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A 203088	001	Jun 11, 2014	May	NEWA
AB		EQ 30MG BASE	A 203088	002	Jun 11, 2014	May	NEWA
AB		EQ 60MG BASE	A 203088	003	Jun 11, 2014	May	NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	0.5MG; 0.4MG	A202509	001	Feb 26, 2014	Feb	NEWA
		JALYN						
AB	+	GLAXOSMITHKLINE	0.5MG; 0.4MG	N022460	001	Jun 14, 2010	Feb	CFTG

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+ VELDANA MEDICAL SA 1%

N205175 001 Oct 24, 2013 Feb CAHN

CREAM; TOPICAL

SPECTAZOLE

@ MERZ PHARMS LLC 1%

N018751 001 Dec 23, 1982 Jan CAHN

>A> EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

>A>	+	DOW PHARM	10%	N203567	001	Jun 06, 2014	Jun	NEWA
-----	---	-----------	-----	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ WATSON LABS 2.5MG

A075501 001 Aug 22, 2000 May DISC

@ 5MG

A075501 002 Aug 22, 2000 May DISC

@ 10MG

A075501 003 Aug 22, 2000 May DISC

@ 20MG

A075501 004 Aug 22, 2000 May DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014	Jun	NEWA
>A>	AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014	Jun	NEWA
>A>	AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014	Jun	NEWA
>A>	AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014	Jun	NEWA
>A>	AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014	Jun	NEWA
>A>	AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014	Jun	NEWA
>A>	AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014	Jun	NEWA

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS 1MG/ML

N204200 001 Dec 07, 2012 Apr CAHN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS 30MG/30ML (1MG/ML)

N204640 001 Dec 18, 2013 Apr CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

@ HOSPIRA 50MG/25ML (2MG/ML)

A065343 002 Apr 19, 2007 May DISC

@ MUSTAFA NEVSAT 50MG/25ML (2MG/ML)

A090266 001 Apr 15, 2011 Mar DISC

@ 200MG/100ML (2MG/ML)

A090266 002 Apr 15, 2011 Mar DISC

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

>D>	+	HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Jun	DISC
>A>		@	50MG/VIAL	N050807	001	Sep 15, 2006	Jun	DISC

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

@ WATSON LABS 0.5MG

A087233 001 May DISC

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	May	NEWA
AB			EQ 100MG BASE	A091002	002	Jun 11, 2014	May	NEWA
AB			EQ 150MG BASE	A091002	003	Jun 11, 2014	May	NEWA

<u>TABLET; ORAL</u>								
TARCEVA								
AB	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	May	CFTG	
AB		EQ 100MG BASE	N021743	002	Nov 18, 2004	May	CFTG	
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	May	CFTG	
<u>ERYTHROMYCIN</u>								
SWAB; TOPICAL								
ERYTHROMYCIN								
	@ FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	May	DISC	
<u>ERYTHROMYCIN LACTOBIONATE</u>								
INJECTABLE; INJECTION								
ERYTHROCIN								
+	HOSPIRA	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	May	CTEC	
<u>ERYTHROMYCIN STEARATE</u>								
TABLET; ORAL								
ERYTHROMYCIN STEARATE								
	@ ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb	CAHN	
	@	EQ 250MG BASE	A061591	001		Jan	CAHN	
	@	EQ 500MG BASE	A061461	002		Feb	CAHN	
	@	EQ 500MG BASE	A063179	001	May 15, 1990	Feb	CAHN	
<u>ESCITALOPRAM OXALATE</u>								
TABLET; ORAL								
ESCITALOPRAM OXALATE								
AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	CAHN	
AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	CAHN	
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	CAHN	
<u>ESOMEPRAZOLE MAGNESIUM</u>								
CAPSULE, DELAYED RELEASE; ORAL								
NEXIUM								
	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar	NEWA	
<u>ESTRADIOL</u>								
GEL; TOPICAL								
ESTROGEL								
	@ ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004	May	CAHN	
GEL; TRANSDERMAL								
DIVIGEL								
	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Apr	CAHN	
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Apr	CAHN	
+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Apr	CAHN	
GEL, METERED; TRANSDERMAL								
ESTROGEL								
+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	May	CAHN	
SPRAY; TRANSDERMAL								
EVAMIST								
+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN	
<u>ESTRADIOL CYPIONATE</u>								
INJECTABLE; INJECTION								
DEPO-ESTRADIOL								
+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003		May	CTEC	
ESTRADIOL CYPIONATE								
	@ WATSON LABS	5MG/ML	A085620	001		May	DISC	
<u>ESTRADIOL VALERATE</u>								
INJECTABLE; INJECTION								
DELESTROGEN								
AO	+	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr	CAHN
AO	+		20MG/ML	N009402	004		Apr	CAHN
AO	+		40MG/ML	N009402	003		Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

>A>	AB	AMNEAL PHARMS LLC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Jun	CAHN
>A>	AB	+	1MG;0.5MG	N020907	001	Nov 18, 1998	Jun	CAHN
>D>	AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Jun	CAHN
>D>	AB	+	1MG;0.5MG	N020907	001	Nov 18, 1998	Jun	CAHN

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

		@ WATSON LABS	6MG	A081216	001	Sep 23, 1993	May	DISC
		OGEN 5						
		PHARMACIA AND UPJOHN	6MG	A083220	004		May	CTEC
		ORTHO-EST						
>D>		@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Jun	CAHN
>D>		@	1.5MG	A089582	001	Jul 17, 1991	Jun	CAHN
>A>		@ SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991	Jun	CAHN
>A>		@	1.5MG	A089582	001	Jul 17, 1991	Jun	CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB		DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091024	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091024	003	Apr 15, 2014	Mar	NEWA
AB		GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091166	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091166	003	Apr 15, 2014	Mar	NEWA
AB		LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar	CMFD
AB			2MG	A091124	002	Sep 13, 2011	Mar	CMFD
AB			3MG	A091124	003	Sep 13, 2011	Mar	CMFD
AB		ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014	May	NEWA
AB			2MG	A091113	002	Jun 10, 2014	May	NEWA
AB			3MG	A091113	003	Jun 10, 2014	May	NEWA
AB		ROXANE	1MG	A091153	001	Apr 15, 2014	Mar	NEWA
AB			2MG	A091153	002	Apr 15, 2014	Mar	NEWA
AB			3MG	A091153	003	Apr 15, 2014	Mar	NEWA
AB		TEVA	1MG	A091169	001	May 23, 2011	Jan	CMFD
AB			2MG	A091169	002	May 23, 2011	Jan	CMFD
AB			3MG	A091169	003	May 23, 2011	Jan	CMFD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+		ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Apr	CPOT
---	--	-----------------	--------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan	NEWA
-----	--	--------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CFTG
	+		0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CPOT
AB		XULANE						
AB		MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

		@ WATSON LABS	0.035MG;1MG	A071480	001	Apr 12, 1988	May	DISC
		NORETHINDRONE AND ETHINYL ESTRADIOL						
		@ WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010	May	DISC
		@	0.035MG;1MG	A070685	001	Jan 29, 1987	May	DISC
		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
		@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988	May	DISC
		NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)						
		@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May	DISC

	TABLET;ORAL-28						
	NORETHIN 1/35E-28						
	@ WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988	May	DISC
	NORETHINDRONE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75	A076393	001	Feb 04, 2010	May	DISC
		MG,1MG					
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)						
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991	May	DISC
	TABLET, CHEWABLE;ORAL						
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	FAMY CARE LTD	0.025MG;0.8MG	A203371	001	Apr 23, 2014	Apr	NEWA
AB	+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr	CFTG
	<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>						
	TABLET;ORAL-21						
	GILDESS 1.5/30						
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar	NEWA
	GILDESS 1/20						
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar	NEWA
	LARIN 1.5/30						
AB	NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar	NEWA
	LOESTRIN 21 1.5/30						
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		May	DISC
	LOESTRIN 21 1/20						
	@ WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		May	DISC
	TABLET;ORAL-28						
	LOESTRIN FE 1.5/30						
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		May	DISC
	LOESTRIN FE 1/20						
	@ WARNER CHILCOTT	0.02MG;1MG	N017354	001		May	DISC
	MICROGESTIN FE 1.5/30						
AB	+ WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	May	CRLD
	<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>						
	TABLET;ORAL-28						
	NORGESTIMATE AND ETHINYL ESTRADIOL						
	@ WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A090479	001	Mar 09, 2011	May	DISC
		15MG,0.25MG					
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076626	001	Aug 17, 2006	May	DISC
		15MG,0.25MG					
	@	0.035MG;0.25MG	A076627	001	Aug 17, 2006	May	DISC
	<u>ETHINYL ESTRADIOL; NORGESTREL</u>						
	TABLET;ORAL-21						
	LOW-OGESTREL-21						
	@ WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	May	DISC
	TABLET;ORAL-28						
	LOW-OGESTREL-28						
	@ WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	May	DISC
	<u>ETHIODIZED OIL</u>						
	OIL;INTRALYMPHATIC, INTRAUTERINE						
	ETHIODOL						
	+ GUERBET	99%	N009190	001		Apr	CMFD
	LIPIODOL						
	+ GUERBET	99%	N009190	001		Apr	CTNA
	<u>ETODOLAC</u>						
	CAPSULE;ORAL						
	ETODOLAC						
	@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN
	@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN
	@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN
AB		300MG	A075126	002	Sep 16, 1999	Jan	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	ETODOLAC						
AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May	NEWA
AB		500MG	A091134	002	Jan 23, 2014	May	NEWA
AB		600MG	A091134	003	Jan 23, 2014	May	NEWA

ETOMIDATE

	INJECTABLE; INJECTION						
	ETOMIDATE						
AP	AGILA SPECLTS	2MG/ML		A078289	001	Jan 02, 2009	Feb CAHN

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

	@ PHARMACHEMIE BV	20MG/ML		A074227	001	Feb 22, 1996	Feb CAHN
	@ TEVA PHARMS USA	20MG/ML		A074284	001	Feb 10, 1994	May DISC

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON

>D>	+	AMYLIN	2MG/VIAL		N022200	001	Jan 27, 2012	Jun CAHN
>A>	+	ASTRAZENECA AB	2MG/VIAL		N022200	001	Jan 27, 2012	Jun CAHN
		INJECTABLE; SUBCUTANEOUS						
		BYETTA						
	+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)		N021773	001	Apr 28, 2005	Mar CAHN
	+		600MCG/2.4ML (250MCG/ML)		N021773	002	Apr 28, 2005	Mar CAHN

FAMOTIDINE

FOR SUSPENSION; ORAL
FAMOTIDINE

AB	HI-TECH PHARMA CO	40MG/5ML		A201995	001	May 30, 2014	May NEWA
	INJECTABLE; INJECTION						
	FAMOTIDINE PRESERVATIVE FREE						
AP	BEDFORD LABS	10MG/ML		A075825	001	Apr 17, 2001	Feb CAHN

FENOFIBRATE

TABLET; ORAL
FENOGLIDE

	SANTARUS INC	40MG		N022118	001	Aug 10, 2007	Feb CAHN
+		120MG		N022118	002	Aug 10, 2007	Feb CAHN
	TRIGLIDE						
	@ SKYEPHARMA AG	50MG		N021350	001	May 07, 2005	May DISC

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

	@ NOVEN	100MCG/HR		A077775	004	Oct 16, 2009	Apr DISC
	FENTANYL-25						
	@ NOVEN	25MCG/HR		A077775	001	Oct 16, 2009	Apr DISC
	FENTANYL-50						
	@ NOVEN	50MCG/HR		A077775	002	Oct 16, 2009	Apr DISC
	FENTANYL-75						
	@ NOVEN	75MCG/HR		A077775	003	Oct 16, 2009	Apr DISC

FENTANYL CITRATE

TABLET; BUCCAL
FENTANYL CITRATE

	@ WATSON LABS	EQ 0.1MG BASE		A079075	001	Jan 07, 2011	May DISC	
	@	EQ 0.2MG BASE		A079075	002	Jan 07, 2011	May DISC	
	@	EQ 0.4MG BASE		A079075	003	Jan 07, 2011	May DISC	
	@	EQ 0.6MG BASE		A079075	004	Jan 07, 2011	May DISC	
	@	EQ 0.8MG BASE		A079075	005	Jan 07, 2011	May DISC	
>A>	TABLET; BUCCAL, SUBLINGUAL							
>A>	FENTANYL CITRATE							
>A>	@ WATSON LABS	EQ 0.1MG BASE		A079075	001	Jan 07, 2011	Jun CDFR	
>A>	@	EQ 0.2MG BASE		A079075	002	Jan 07, 2011	Jun CDFR	
>A>	@	EQ 0.4MG BASE		A079075	003	Jan 07, 2011	Jun CDFR	
>A>	@	EQ 0.6MG BASE		A079075	004	Jan 07, 2011	Jun CDFR	
>A>	@	EQ 0.8MG BASE		A079075	005	Jan 07, 2011	Jun CDFR	
	FENTORA							
>D>	AB	CEPHALON	EQ 0.1MG BASE		N021947	001	Sep 25, 2006	Jun CTEC
>A>			EQ 0.1MG BASE		N021947	001	Sep 25, 2006	Jun CTEC
>A>	AB		EQ 0.1MG BASE		N021947	001	Sep 25, 2006	Jun CTEC
>D>	AB		EQ 0.2MG BASE		N021947	002	Sep 25, 2006	Jun CTEC
>A>			EQ 0.2MG BASE		N021947	002	Sep 25, 2006	Jun CTEC
>D>	AB	+	EQ 0.4MG BASE		N021947	003	Sep 25, 2006	Jun CTEC
>A>		+	EQ 0.4MG BASE		N021947	003	Sep 25, 2006	Jun CTEC

TABLET;BUCCAL, SUBLINGUAL
FENTORA

>D>	AB	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Jun CTEC	
>A>		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Jun CTEC	
>D>	AB	EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Jun CTEC	
>A>		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Jun CTEC	
>D>	TABLET;SUBLINGUAL						
>D>	FENTANYL CITRATE						
>D>	@	WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011	Jun CDFR
	@		EQ 0.1MG BASE	A079075	001	Jan 07, 2011	May CDFR
>D>	@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	Jun CDFR
	@		EQ 0.2MG BASE	A079075	002	Jan 07, 2011	May CDFR
>D>	@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	Jun CDFR
	@		EQ 0.4MG BASE	A079075	003	Jan 07, 2011	May CDFR
>D>	@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	Jun CDFR
	@		EQ 0.6MG BASE	A079075	004	Jan 07, 2011	May CDFR
>D>	@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	Jun CDFR
	@		EQ 0.8MG BASE	A079075	005	Jan 07, 2011	May CDFR

FLORBETABEN F-18

SOLUTION;INTRAVENOUS
NEURACEQ

+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar NEWA
---	-----------------	----------------------	---------	-----	--------------	----------

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr DISC
@		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	May CAHN
----	---------------------	--------------------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan NEWA	
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan NEWA	
AP	UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr NEWA	
	@	WELL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb DISC
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan NEWA	

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB	HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

+	MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar CAHN
---	-----------------	------------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

+	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Apr CMFD
---	--------------------	-------------------------	---------	-----	--	----------

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

>A>	AB	FOUGERA PHARMS INC	0.1%	A200735	001	Jul 14, 2014	Jun NEWA
>A>	AB	GLENMARK GENERICS	0.1%	A091282	001	Jul 14, 2014	Jun NEWA
>A>	AB	TARO	0.1%	A200734	001	Jul 14, 2014	Jun NEWA

SOLUTION;TOPICAL

FLUOCINONIDE

AT	G AND W LABS INC	0.05%	A071535	001	Dec 02, 1988	May CAHN
----	------------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL							
LIDEX							
AT	CNTY LINE PHARMS	0.05%		N018849	001	Apr 06, 1984	Apr CMFD
<u>FLUOXETINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
FLUOXETINE HYDROCHLORIDE							
AB2	ANI PHARMS INC	EQ 10MG BASE		A076287	001	May 20, 2008	Jan CAHN
AB2		EQ 20MG BASE		A076287	002	May 20, 2008	Jan CAHN
TABLET;ORAL							
SARAFEM							
AB1	WARNER CHILCOTT LLC	EQ 10MG BASE		N021860	001	May 19, 2006	Jan CFTG
AB1		EQ 15MG BASE		N021860	002	May 19, 2006	Jan CFTG
AB1	+	EQ 20MG BASE		N021860	003	May 19, 2006	Jan CFTG
SELFEMRA							
AB1	TEVA PHARMS USA	EQ 10MG BASE		A200151	001	Feb 03, 2014	Jan NEWA
AB1		EQ 15MG BASE		A200151	002	Feb 03, 2014	Jan NEWA
AB1		EQ 20MG BASE		A200151	003	Feb 03, 2014	Jan NEWA
<u>FLUPHENAZINE DECANOATE</u>							
INJECTABLE;INJECTION							
FLUPHENAZINE DECANOATE							
>A>	AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Jun NEWA
<u>FLUPHENAZINE HYDROCHLORIDE</u>							
ELIXIR;ORAL							
FLUPHENAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC		2.5MG/5ML	A081310	001	Apr 29, 1993	Feb CAHN
<u>FLURAZEPAM HYDROCHLORIDE</u>							
CAPSULE;ORAL							
FLURAZEPAM HYDROCHLORIDE							
	MYLAN PHARMS INC	15MG		A070345	002	Nov 27, 1985	May CTEC
	+	30MG		A070345	001	Nov 27, 1985	May CTEC
	@ WATSON LABS	15MG		A071205	001	Nov 25, 1986	May DISC
	@	30MG		A071068	001	Nov 25, 1986	May DISC
	@	30MG		A072369	001	Mar 30, 1989	May DISC
<u>FOLIC ACID</u>							
TABLET;ORAL							
FOLIC ACID							
AA	CADILA PHARMS LTD	1 MG		A202437	001	Jan 27, 2014	Jan NEWA
<u>FOLLITROPIN ALFA/BETA</u>							
INJECTABLE;SUBCUTANEOUS							
GONAL-F RFF REDI-JECT							
	+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May CTNA
	+		450 IU/0.75ML	N021684	002	May 25, 2004	May CTNA
	+		900 IU/1.5ML	N021684	003	May 25, 2004	May CTNA
<u>FOMEPIZOLE</u>							
INJECTABLE;INJECTION							
FOMEPIZOLE							
>D>	AP	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun DISC
>A>		@	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun DISC
<u>FONDAPARINUX SODIUM</u>							
INJECTABLE;SUBCUTANEOUS							
ARIIXTRA							
AP	+	AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	May CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	May CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	May CAHN
<u>FOSINOPRIL SODIUM</u>							
TABLET;ORAL							
FOSINOPRIL SODIUM							
	@ WATSON LABS		10MG	A077531	001	Aug 31, 2006	May DISC
	@		20MG	A077531	002	Aug 31, 2006	May DISC
	@		40MG	A077531	003	Aug 31, 2006	May DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
AB	+		20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CRLD
----	---	---------------------	-------------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD
		FOSPHENYTOIN SODIUM						

AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN
----	--	---------------	-------------------------	---------	-----	--------------	-----	------

>D>	AP	AMNEAL PHARMS	EQ 50MG PNEYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun	CAHN
-----	----	---------------	------------------------	---------	-----	--------------	-----	------

>A>	AP	AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun	CAHN
-----	----	------------------	-------------------------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan	NEWA
----	--	---------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

FUROSEMIDE

AB		CARACO	20MG	A091258	001	Apr 01, 2014	Mar	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

AB			40MG	A091258	002	Apr 01, 2014	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			80MG	A091258	003	Apr 01, 2014	Mar	NEWA
----	--	--	------	---------	-----	--------------	-----	------

		@ WATSON LABS	20MG	A070412	001	Feb 26, 1986	May	DISC
--	--	---------------	------	---------	-----	--------------	-----	------

		@	20MG	A070449	001	Nov 22, 1985	May	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	20MG	A071379	001	Jan 02, 1987	May	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	40MG	A070450	001	Nov 22, 1985	May	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	80MG	A070528	001	Jan 07, 1986	May	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	80MG	A071594	001	Feb 09, 1988	May	DISC
--	--	---	------	---------	-----	--------------	-----	------

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

		@ WATSON LABS	100MG	A075485	003	May 11, 2007	May	DISC
--	--	---------------	-------	---------	-----	--------------	-----	------

		@	300MG	A075485	002	May 11, 2007	May	DISC
--	--	---	-------	---------	-----	--------------	-----	------

		@	400MG	A075485	001	May 11, 2007	May	DISC
--	--	---	-------	---------	-----	--------------	-----	------

TABLET; ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

AB			800MG	A203244	001	Jul 12, 2013	Feb	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

		@ YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CAHN
--	--	---------------	-------------	---------	-----	--------------	-----	------

		@	EQ 8MG BASE	A077604	002	Feb 06, 2009	May	CAHN
--	--	---	-------------	---------	-----	--------------	-----	------

		@	EQ 12MG BASE	A077604	003	Feb 06, 2009	May	CAHN
--	--	---	--------------	---------	-----	--------------	-----	------

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

>D>	AB	CARACO	600MG	A079239	001	Dec 29, 2008	Jun	CAHN
-----	----	--------	-------	---------	-----	--------------	-----	------

>A>	AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

		@ WATSON LABS	600MG	A074442	001	Apr 28, 1995	May	DISC
--	--	---------------	-------	---------	-----	--------------	-----	------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

	+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan	NEWA
--	---	-----------------	---------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	WATSON LABS	1MG	A 077280	001	Feb 03, 2006	May	DISC
@		2MG	A 077280	002	Feb 03, 2006	May	DISC
@		4MG	A 077280	003	Feb 03, 2006	May	DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@	WATSON LABS	5MG	A 074370	001	Nov 22, 1994	May	DISC
@		10MG	A 074370	002	Nov 22, 1994	May	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A 091182	001	Feb 03, 2014	Jan	NEWA
AA		2MG	A 091182	002	Feb 03, 2014	Jan	NEWA
AA	VINTAGE PHARMS	1MG	A 090020	001	Oct 19, 2011	Feb	CAHN
AA		2MG	A 090020	002	Oct 19, 2011	Feb	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	@	EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078808	001	Apr 29, 2008	Jun	CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078835	001	Jun 30, 2008	Jun	CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078835	002	Jun 30, 2008	Jun	CAHN
>A>	@	SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078808	001	Apr 29, 2008	Jun	CAHN
>A>	AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078835	001	Jun 30, 2008	Jun	CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078835	002	Jun 30, 2008	Jun	CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

		ANI PHARMS INC	EQ 4MG BASE	A 074149	001	Apr 07, 1995	Jan	CAHN
	@		EQ 4MG BASE	A 074267	001	Jun 01, 1994	Mar	CAHN
	+		EQ 8MG BASE	A 074149	002	Apr 07, 1995	Jan	CAHN
	@		EQ 8MG BASE	A 074267	002	Jun 01, 1994	Mar	CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		TARO	0.05%	A 076994	001	Dec 16, 2004	Apr	CMFD
----	--	------	-------	----------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO		AGILA SPECLTS	EQ 50MG BASE/ML	A 075440	001	Feb 28, 2000	Feb	CMFD
AO			EQ 100MG BASE/ML	A 075440	002	Feb 28, 2000	Feb	CMFD

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	+	FRESENIUS KABI USA	10,000 UNITS/ML	N 017029	020	Mar 31, 2011	Mar	NEWA
	+	HOSPIRA	5,000 UNITS/ML	A 088100	001	Apr 28, 1983	Mar	CRLD
	+	PFIZER	1,000 UNITS/ML	N 201370	001	Jul 21, 2011	Mar	CRLD
	+		5,000 UNITS/ML	N 201370	002	Jul 21, 2011	Mar	CRLD
	+		10,000 UNITS/ML	N 201370	003	Jul 21, 2011	Mar	CRLD
>A>	AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A 202957	001	Jun 12, 2014	Jun	NEWA
>A>	AP		5,000 UNITS/ML	A 202733	001	Jun 12, 2014	Jun	NEWA
>A>	AP		5,000 UNITS/ML	A 202957	002	Jun 12, 2014	Jun	NEWA
>A>	AP		10,000 UNITS/ML	A 203198	001	Jun 12, 2014	Jun	NEWA
>A>	AP		20,000 UNITS/ML	A 203198	002	Jun 12, 2014	Jun	NEWA
		HEPARIN SODIUM IN PLASTIC CONTAINER						
>D>	+	FRESENIUS KABI USA	1,000 UNITS/ML	N 017029	013	Dec 05, 1985	Jun	CTEC
>A>	AP		1,000 UNITS/ML	N 017029	013	Dec 05, 1985	Jun	CTEC
	+		1,000 UNITS/ML	N 017029	013	Dec 05, 1985	Mar	CTEC
>D>	+		10,000 UNITS/ML	N 017029	015	Dec 05, 1985	Jun	CTEC
>A>	AP		10,000 UNITS/ML	N 017029	015	Dec 05, 1985	Jun	CTEC
	+		10,000 UNITS/ML	N 017029	015	Dec 05, 1985	Mar	CTEC

INJECTABLE; INJECTION

HEPARIN SODIUM IN PLASTIC CONTAINER

>D>	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun CTEC
>A>	AP	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun CTEC
		+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC
			HEPARIN SODIUM PRESERVATIVE FREE				
		+	FRESENIUS KABI USA 10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar NEWA
		+	HOSPIRA 10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
		+	PFIZER 1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD
>A>	AP		SHENZHEN TECHDOW 1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jun NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@	WATSON LABS	25MG	A084504	001		May DISC
	@		50MG	A084503	001		May DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar NEWA
----	--	--------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG; 150MG	A203072	001	May 09, 2014	Apr NEWA
AB			12.5MG; 300MG	A203072	002	May 09, 2014	Apr NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@	WATSON LABS	12.5MG; 50MG	A200180	001	Jan 12, 2011	May DISC
	@		12.5MG; 100MG	A200180	002	Jan 12, 2011	May DISC
	@		25MG; 100MG	A200180	003	Jan 12, 2011	May DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986	Mar CMS1
--	--	-------	-------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

>D>		ASTRAZENECA	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
>D>			12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
>D>	+		12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN
>A>		COVIS PHARMA SARL	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
>A>			12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
>A>	+		12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr CAHN
AB			12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr CAHN
AB			25MG; 15MG	A202150	003	Mar 07, 2014	Apr CAHN
AB		INDICUS PHARMA	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Feb NEWA
AB			12.5MG; 15MG	A202150	002	Mar 07, 2014	Feb NEWA
AB			25MG; 15MG	A202150	003	Mar 07, 2014	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	25MG; 40MG	A070947	002	Mar 04, 1987	Mar CMS1
----	--	-------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

	@	WATSON LABS	25MG; 25MG	A087398	001		May DISC
--	---	-------------	------------	---------	-----	--	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL		MICARDIS HCT						
AB	BOEHRINGER INGELHEIM	12.5MG; 40MG		N021162	001	Nov 17, 2000	Feb	CFTG
AB		12.5MG; 80MG		N021162	002	Nov 17, 2000	Feb	CFTG
AB	+	25MG; 80MG		N021162	003	Apr 19, 2004	Feb	CFTG
TELMISARTAN AND HYDROCHLOROTHIAZIDE								
AB	ALEMBIC PHARMS LTD	12.5MG; 40MG		A203010	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG; 80MG		A203010	002	Feb 25, 2014	Feb	NEWA
AB		25MG; 80MG		A203010	003	Feb 25, 2014	Feb	NEWA
AB	MYLAN PHARMS INC	12.5MG; 40MG		A091648	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG; 80MG		A091648	002	Feb 25, 2014	Feb	NEWA
AB		25MG; 80MG		A091648	003	Feb 25, 2014	Feb	NEWA
AB	TORRENT PHARMS LTD	12.5MG; 40MG		A201192	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG; 80MG		A201192	002	Feb 25, 2014	Feb	NEWA
AB		25MG; 80MG		A201192	003	Feb 25, 2014	Feb	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL		HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
AA	PADDOCK LLC	5MG/5ML; 60MG/5ML		A204658	001	Apr 29, 2014	Apr	NEWA
		REZIRA						
AA	+	CYPRESS PHARM	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Apr	CFTG

HYDROCORTISONE

CREAM; TOPICAL		HYDROCORTISONE						
	@ TARO	1%		A086155	001		Mar	DISC
LOTION; TOPICAL		ALA-CORT						
	@ CROWN LABS	1%		A083201	001		Mar	DISC
	NUTRACORT							
	@ DOW PHARM	1%		A080443	003		Mar	DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL		HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%						
	@ VINTAGE PHARMS	1%; 1%		A089440	001	May 17, 1988	Feb	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		EXALGO						
AB	MALLINCKRODT INC	8MG		N021217	001	Mar 01, 2010	Apr	CFTG
AB		12MG		N021217	002	Mar 01, 2010	Apr	CFTG
AB		16MG		N021217	003	Mar 01, 2010	Apr	CFTG
HYDROMORPHONE HYDROCHLORIDE								
AB	ACTAVIS LABS FL INC	8MG		A202144	001	May 12, 2014	Apr	NEWA
AB		12MG		A202144	002	May 12, 2014	Apr	NEWA
AB		16MG		A202144	003	May 12, 2014	Apr	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL		HYDROXYCHLOROQUINE SULFATE						
	@ WATSON LABS	200MG		A040133	001	Nov 30, 1995	May	DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR		MAKENA						
+	LUMARA HEALTH INC	1250MG/5ML (250MG/ML)		N021945	001	Feb 03, 2011	May	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL		HYDROXYZINE HYDROCHLORIDE						
>D>	AB	CARACO	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
>D>	AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
>D>	AB		50MG	A040899	003	Jun 10, 2008	Jun	CAHN
>A>	AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
>A>	AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
>A>	AB		50MG	A040899	003	Jun 10, 2008	Jun	CAHN
		@ WATSON LABS	10MG	A081149	001	Mar 18, 1994	May	DISC
		@	25MG	A081150	001	Mar 18, 1994	May	DISC

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@	50MG	A081151	001	Mar 18, 1994	May DISC
---	------	---------	-----	--------------	----------

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

>D>	AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	Jun CPOT
>A>	AB		EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Jun CPOT
>D>	AB		50MG	A201507	002	Jun 03, 2013	Jun CPOT
>A>	AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jun CPOT
		@ WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
		IBANDRONATE SODIUM					
AP		SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

@	WATSON LABS	400MG	A070436	001	Aug 21, 1985	May DISC
@		600MG	A070437	001	Aug 21, 1985	May DISC

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

>A>	AB	STRIDES ARCOLAB LTD	5%	A202002	001	Jun 24, 2014	Jun NEWA
-----	----	---------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

@	WATSON LABS	1.25MG	A074585	001	Sep 26, 1996	May DISC
@		2.5MG	A074585	002	Sep 26, 1996	May DISC

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

@	IROKO PHARMS LLC	25MG	N016059	001		May CAHN
@		50MG	N016059	002		May CAHN

INDOMETHACIN

>D>	AB	CARACO	25MG	A091401	001	Mar 28, 2013	Jun CAHN
>D>	AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN
>A>	AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun CAHN
>A>	AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN

TIVORBEX

		IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
	+		40MG	N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

AB		MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar NEWA
----	--	------------------	------	---------	-----	--------------	----------

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

>A> POWDER;INHALATION

AFREZZA

>A>		MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Jun NEWA
>A>	+		8 UNITS/INH	N022472	002	Jun 27, 2014	Jun NEWA

IPRATROPIUM BROMIDE

		SOLUTION; INHALATION							
		IPRATROPIUM BROMIDE							
AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar	CAHN	
		SPRAY, METERED; NASAL							
		IPRATROPIUM BROMIDE							
AB		MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May	CAHN	
AB			0.042MG/SPRAY	A075553	001	Mar 31, 2003	May	CAHN	

IRINOTECAN HYDROCHLORIDE

		INJECTABLE; INJECTION							
		IRINOTECAN HYDROCHLORIDE							
AP		MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	CAHN	
AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	CAHN	

ISOFLURANE

		LIQUID; INHALATION							
		ISOFLURANE							
AN		PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb	CAHN	

ISOSORBIDE DINITRATE

		CAPSULE, EXTENDED RELEASE; ORAL							
		DILATRATE-SR							
	+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Apr	CAHN	

ISOSORBIDE MONONITRATE

		TABLET; ORAL							
		ISOSORBIDE MONONITRATE							
AB		ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan	CAHN	
		TABLET, EXTENDED RELEASE; ORAL							
		ISOSORBIDE MONONITRATE							
	@	ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998	May	DISC	
	@		60MG	A075306	002	Dec 31, 1998	May	DISC	

ISRADIPINE

		CAPSULE; ORAL							
		ISRADIPINE							
AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	May	CMFD	
	@		2.5MG	A077169	001	Apr 24, 2006	Feb	DISC	
AB			5MG	A077169	002	Apr 24, 2006	May	CMFD	
	@		5MG	A077169	002	Apr 24, 2006	Feb	DISC	
AB		WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	May	CTEC	
			2.5MG	A077317	001	Jan 05, 2006	Feb	CTEC	
AB	+		5MG	A077317	002	Jan 05, 2006	May	CTEC	
	+		5MG	A077317	002	Jan 05, 2006	Feb	CTEC	

KETAMINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		KETALAR							
AP	+	PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr	CAHN	
AP	+		EQ 50MG BASE/ML	N016812	002		Apr	CAHN	
AP	+		EQ 100MG BASE/ML	N016812	003		Apr	CAHN	

KETOCONAZOLE

		AEROSOL, FOAM; TOPICAL							
		EXTINA							
>A>	AT	+	DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun	CAHN
>D>	AT	+	STIEFEL LABS INC	2%	N021738	001	Jun 12, 2007	Jun	CAHN
		TABLET; ORAL							
		NIZORAL							
AB	+	JANSSEN PHARMS	200MG	N018533	001		Mar	CAHN	

KETOROLAC TROMETHAMINE

		INJECTABLE; INJECTION							
		KETOROLAC TROMETHAMINE							
>D>	AP		HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
>A>		@		15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
>D>	AP			15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
>A>		@		15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
>D>	AP			30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC
>A>		@		30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D>	AP		30MG/ML	A075772	002	Jul 21, 2004	Jun DISC
>A>	@		30MG/ML	A075772	002	Jul 21, 2004	Jun DISC
>D>	AP	WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun DISC
>A>	@		30MG/ML	A077943	001	Mar 27, 2007	Jun DISC

SOLUTION/DROPS; OPHTHALMIC

ACUVAIL

AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan CFTG
		KETOROLAC TROMETHAMINE					
		@ AKORN	0.45%	A203376	001	Feb 10, 2014	Feb DISC
AT			0.45%	A203376	001	Feb 10, 2014	Jan NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

>D>	+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Jun CPOT
>A>	+		EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun CPOT
	+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		HETERO LABS LTD V	150MG; 300MG	A203259	001	Feb 03, 2014	Jan NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ ACTAVIS TOTOWA

@

@

@

			25MG	A078669	001	Apr 08, 2011	May DISC
			100MG	A078669	002	Apr 08, 2011	May DISC
			150MG	A078669	003	Apr 08, 2011	May DISC
			200MG	A078669	004	Apr 08, 2011	May DISC
		TABLET, CHEWABLE; ORAL					
		LAMOTRIGINE					
AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May NEWA
AB			25MG	A201168	002	Jun 12, 2014	May NEWA

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@ ANI PHARMS INC

@

			15MG	A078730	001	Oct 15, 2010	Jan CAHN
			30MG	A078730	002	Oct 15, 2010	Jan CAHN
		TABLET; ORAL					
		LETROZOLE					
		@ ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	May DISC

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

@ ABBVIE ENDOCRINE INC

+

			3.75MG/VIAL	N020011	001	Oct 22, 1990	May DISC
			3.75MG	N020011	002	Oct 26, 1995	May NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		MYLAN SPECLT	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	May CAHN
AN			EQ 0.021% BASE	A077800	002	Mar 15, 2013	May CAHN
AN			EQ 0.042% BASE	A077800	003	Mar 15, 2013	May CAHN
>D>	@	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun CMFD
>A>	AN		EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun CMFD
	@		EQ 0.0103% BASE	A077756	003	Apr 09, 2008	May DISC
>D>	@		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun CMFD
>A>	AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun CMFD
	@		EQ 0.021% BASE	A077756	001	Apr 09, 2008	May DISC
>D>	@		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun CMFD
>A>	AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun CMFD
	@		EQ 0.042% BASE	A077756	002	Apr 09, 2008	May DISC

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

>D>	AB	SANDOZ	1GM	A 077324	004	Jan 15, 2009	Jun	DISC
>A>		@	1GM	A 077324	004	Jan 15, 2009	Jun	DISC
>D>	AB		250MG	A 077324	001	Jan 15, 2009	Jun	DISC
>A>		@	250MG	A 077324	001	Jan 15, 2009	Jun	DISC
>D>	AB		500MG	A 077324	002	Jan 15, 2009	Jun	DISC
>A>		@	500MG	A 077324	002	Jan 15, 2009	Jun	DISC
>D>	AB		750MG	A 077324	003	Jan 15, 2009	Jun	DISC
>A>		@	750MG	A 077324	003	Jan 15, 2009	Jun	DISC
	AB	VINTAGE PHARMS	250MG	A 077319	001	Mar 20, 2009	Feb	CAHN
	AB		500MG	A 077319	002	Mar 20, 2009	Feb	CAHN
	AB		750MG	A 077319	003	Mar 20, 2009	Feb	CAHN
		@ WATSON LABS INC	1GM	A 078797	001	Jan 15, 2009	May	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	VINTAGE PHARMS	500MG	A 201464	001	May 25, 2012	Feb	CAHN
	AB		750MG	A 201464	002	May 25, 2012	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		L PERRIGO CO	2.5MG/5ML	A 091263	001	Nov 07, 2011	Jan	CAHN
----	--	--------------	-----------	----------	-----	--------------	-----	------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ SANDOZ

5MG

A 090486	001	Mar 26, 2013	May	DISC
----------	-----	--------------	-----	------

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

IQUIX

>D>								
>D>	+	SANTEN	1.5%	N 021571	001	Mar 01, 2004	Jun	DISC
>A>		@	1.5%	N 021571	001	Mar 01, 2004	Jun	DISC
		LEVOFLOXACIN						
AT		WATSON LABS INC	0.5%	A 076826	001	Feb 10, 2011	May	CAHN

LEVOLEUCOVORIN CALCIUM

>D>		SOLUTION; IV (INFUSION)						
>D>		FUSILEV						
>D>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N 020140	002	Apr 29, 2011	Jun	DISC
>A>		@	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N 020140	002	Apr 29, 2011	Jun	DISC

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE

>A>		@ POPULATION COUNCIL	75MG/IMPLANT	N 020544	001	Nov 01, 1996	Jun	CTNA
>D>		NORPLANT II						
>D>		@ POPULATION COUNCIL	75MG/IMPLANT	N 020544	001	Nov 01, 1996	Jun	CTNA

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ ROXANE

2MG

A 074278	001	Mar 31, 2000	Feb	CRLD
----------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP		AGILA SPECLTS	2%	A 202242	001	Apr 11, 2014	Mar	NEWA
		LIDOPEN						
		@ MERIDIAN MEDCL TECHN	10%	N 017549	001		Mar	DISC
		XYLOCAINE PRESERVATIVE FREE						
>D>	+	FRESENIUS KABI USA	10%	N 016801	003		Jun	DISC
>A>		@	10%	N 016801	003		Jun	DISC
	+		10%	N 016801	003		Mar	CTEC

JELLY; TOPICAL

ANESTACON

>A>		@ BANNER PHARMACAPS	2%	A 080429	001		Jun	CAHN
>D>		@ DSM PHARMS INC	2%	A 080429	001		Jun	CAHN
		@	2%	A 080429	001		Jan	CAHN

		JELLY; TOPICAL							
		GLYDO							
AT		SAGENT PHARMS	2%		A201094	001	Apr 28, 2014	Apr	NEWA
		LIDOCAINE HYDROCHLORIDE							
AT		WATSON LABS INC	2%		A040837	001	Mar 23, 2011	May	CAHN
		SOLUTION; TOPICAL							
		LIDOCAINE HYDROCHLORIDE							
AT		IGI LABS INC	4%		A204494	001	Mar 12, 2014	Feb	NEWA
		SYSTEM; INTRADERMAL							
		ZINGO							
		POWDER PHARMS	0.5MG		N022114	001	Aug 16, 2007	Mar	CMFD
		<u>LIDOCAINE; PRILOCAINE</u>							
		CREAM; TOPICAL							
		EMLA							
AB	+	WATSON LABS INC	2.5%; 2.5%		N019941	001	Dec 30, 1992	May	CAHN
		<u>LIOTHYRONINE SODIUM</u>							
		INJECTABLE; INJECTION							
		TRIOSTAT							
AP	+	PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML		N020105	001	Dec 31, 1991	Apr	CAHN
		<u>LITHIUM CARBONATE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		LITHOBID							
>A>	AB	+	ANI PHARMS INC	300MG	N018027	001		Jun	CAHN
>D>	AB	+	NOVEN THERAP	300MG	N018027	001		Jun	CAHN
		<u>LORAZEPAM</u>							
		INJECTABLE; INJECTION							
		ATIVAN							
>D>	AP	+	BAXTER HLTHCARE CORP	2MG/ML	N018140	001		Jun	CAHN
>D>	AP	+		4MG/ML	N018140	002		Jun	CAHN
>A>	AP	+	HIKMA MAPLE	2MG/ML	N018140	001		Jun	CAHN
>A>	AP	+		4MG/ML	N018140	002		Jun	CAHN
		TABLET; ORAL							
		LORAZEPAM							
		@ WATSON LABS	1MG		A071118	001	Jul 24, 1986	May	DISC
		<u>LOTEPREDNOL ETABONATE</u>							
		GEL; OPHTHALMIC							
		LOTEMAX							
		+ BAUSCH AND LOMB INC	0.5%		N202872	001	Sep 28, 2012	Feb	CAHN
		<u>LULICONAZOLE</u>							
		CREAM; TOPICAL							
		LUZU							
		+ MEDICIS	1%		N204153	001	Nov 14, 2013	Jan	CRLD
		<u>MAGNESIUM SULFATE</u>							
		INJECTABLE; INJECTION							
		MAGNESIUM SULFATE							
>D>	AP		HOSPIRA	500MG/ML	A075151	001	Apr 25, 2000	Jun	CRLD
>A>	AP	+		500MG/ML	A075151	001	Apr 25, 2000	Jun	CRLD
		<u>MALATHION</u>							
		LOTION; TOPICAL							
		MALATHION							
		@ MYLAN PHARMS INC	0.5%		A078743	001	Mar 06, 2009	Mar	DISC
		<u>MEBENDAZOLE</u>							
		TABLET, CHEWABLE; ORAL							
		MEBENDAZOLE							
>A>		+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Jun	CAHN
>D>		+	TEVA PHARMS	100MG	A073580	001	Jan 04, 1995	Jun	CAHN

MECHLORETHAMINE HYDROCHLORIDEGEL;TOPICAL
VALCHLOR

>A>	+	ACTELION PHARMS LTD	EQ 0.016% BASE	N202317	001	Aug 23, 2013	Jun CPOT
>D>	+		0.02%	N202317	001	Aug 23, 2013	Jun CPOT

MECLIZINE HYDROCHLORIDETABLET;ORAL
MECLIZINE HYDROCHLORIDE
@ WATSON LABS

25MG

A085740 001

May DISC

MEDROXYPROGESTERONE ACETATETABLET;ORAL
MEDROXYPROGESTERONE ACETATE
@ USL PHARMA

10MG

A088484 001 Jul 26, 1984 Mar DISC

MEFENAMIC ACIDCAPSULE;ORAL
MEFENAMIC ACID

AB VINTAGE PHARMS LLC 250MG

A091608 001 Jun 02, 2014 May NEWA

MELOXICAMTABLET;ORAL
MELOXICAM@ YABAO PHARM 7.5MG
@ 15MG

A077933 001 Jul 19, 2006 May CAHN

A077933 002 Jul 19, 2006 May CAHN

MEMANTINE HYDROCHLORIDETABLET;ORAL
MEMANTINE HYDROCHLORIDE

>D>		@ DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
>A>	AB		5MG	A090048	001	Apr 14, 2010	Jun CMFD
>D>		@	10MG	A090048	002	Apr 14, 2010	Jun CMFD
>A>	AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
		NAMENDA					
>D>		FOREST LABS	5MG	N021487	001	Oct 16, 2003	Jun CTEC
>A>	AB		5MG	N021487	001	Oct 16, 2003	Jun CTEC
>D>		+	10MG	N021487	002	Oct 16, 2003	Jun CTEC
>A>	AB	+	10MG	N021487	002	Oct 16, 2003	Jun CTEC

MEPERIDINE HYDROCHLORIDEINJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE@ WATSON LABS 50MG/ML
@ 100MG/ML

A073444 001 Mar 17, 1992 May DISC

A073445 001 Mar 17, 1992 May DISC

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 10MG/ML
@ WATSON LABS 10MG/ML

A081309 001 Aug 30, 1993 Mar DISC

A073443 001 Mar 17, 1992 May DISC

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE
@ WATSON LABS 50MG
@ 100MG

A040186 001 Jun 30, 1997 May DISC

A040186 002 Jun 30, 1997 May DISC

MEPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
MEPIVACAINE HYDROCHLORIDE@ WATSON LABS 1%
@ 2%

A088769 001 Nov 20, 1984 May DISC

A088770 001 Nov 20, 1984 May DISC

MERCAPTOPYRINESUSPENSION;ORAL
PURIXAN

+ NOVA LABS LTD 20MG/ML

N205919 001 Apr 28, 2014 Apr NEWA

MESALAMINESUPPOSITORY;RECTAL
CANASA+ FOREST LABS INC 1GM
@ 500MG

N021252 002 Nov 05, 2004 Apr CAHN

N021252 001 Jan 05, 2001 Apr CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

AN	+	MYLAN SPECLT	0.4%	A 071786	001	Aug 05, 1988	May	CAHN
AN	+		0.6%	A 070804	001	Aug 17, 1987	May	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		ATLAS PHARMS LLC	1GM	A 076033	003	Jan 24, 2002	May	CAHN
AB			500MG	A 076033	001	Jan 24, 2002	May	CAHN
AB			850MG	A 076033	002	Jan 24, 2002	May	CAHN
		@ WATSON LABS	1GM	A 075979	003	Jan 24, 2002	May	DISC
		@	500MG	A 075979	001	Jan 24, 2002	May	DISC
		@	850MG	A 075979	002	Jan 24, 2002	May	DISC

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

+		SALIX PHARMS INC	1GM	N 021748	002	Jun 03, 2005	Feb	CTEC
			500MG	N 021748	001	Jun 03, 2005	Feb	CTEC
+		SANTARUS INC	1GM	N 021748	002	Jun 03, 2005	Mar	CAHN
			500MG	N 021748	001	Jun 03, 2005	Mar	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		TEVA PHARMS USA	500MG;EQ 15MG BASE	A 091155	001	Mar 10, 2014	Feb	NEWA
AB			850MG;EQ 15MG BASE	A 091155	002	Mar 10, 2014	Feb	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB		SB PHARMCO	1GM;EQ 2MG BASE	N 021410	004	Aug 25, 2003	Apr	CFTG
AB	+		1GM;EQ 4MG BASE	N 021410	005	Aug 25, 2003	Apr	CFTG
AB			500MG;EQ 2MG BASE	N 021410	002	Oct 10, 2002	Apr	CFTG
AB			500MG;EQ 4MG BASE	N 021410	003	Oct 10, 2002	Apr	CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB		TEVA	1GM;EQ 4MG BASE	A 077337	004	May 07, 2014	Apr	NEWA
AB			1GM;EQ 2MG BASE	A 077337	003	May 07, 2014	Apr	NEWA
AB			500MG;EQ 2MG BASE	A 077337	001	May 07, 2014	Apr	NEWA
AB			500MG;EQ 4MG BASE	A 077337	002	May 07, 2014	Apr	NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

		ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N 200678	003	Nov 05, 2010	Apr	CAHN
+			1GM;EQ 5MG BASE	N 200678	002	Nov 05, 2010	Apr	CAHN
			500MG;EQ 5MG BASE	N 200678	001	Nov 05, 2010	Apr	CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		ANI PHARMS INC	25MG	A 040001	001	Jun 30, 1993	Jan	CAHN
AB			50MG	A 040001	002	Jun 30, 1993	Jan	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		VINTAGE PHARMS	5MG	A 202068	001	Mar 07, 2012	Feb	CAHN
AB			10MG	A 202068	002	Mar 07, 2012	Feb	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

		@ WATSON LABS	500MG	A 085180	001		May	DISC
		@	750MG	A 085192	001		May	DISC
		ROBAXIN						
AA	+	AUXILIUM PHARMS LLC	500MG	N 011011	004		Apr	CAHN
		ROBAXIN-750						
AA	+	AUXILIUM PHARMS LLC	750MG	N 011011	006		Apr	CAHN

METHOHEXITAL SODIUMINJECTABLE; INJECTION
BREVITAL SODIUM

+	PAR STERILE PRODUCTS	2.5GM/VIAL		N011559	002		Apr	CAHN
	@	5GM/VIAL		N011559	003		Apr	CAHN
+		200MG/VIAL		N011559	004	Dec 21, 2012	Apr	CAHN
+		500MG/VIAL		N011559	001		Apr	CAHN

METHOXSALENCAPSULE; ORAL
METHOXSALEN

AB	STRIDES ARCOLAB LTD	10MG		A202687	001	Jun 05, 2014	May	NEWA
AB	+ DOW PHARM	10MG		N019600	001	Oct 30, 1986	May	CTEC

METHSCOPOLAMINE BROMIDETABLET; ORAL
METHSCOPOLAMINE BROMIDE

AA	VINTAGE PHARMS	2.5MG		A040624	001	Dec 28, 2006	Feb	CAHN
AA		5MG		A040624	002	Dec 28, 2006	Feb	CAHN

METHYLDOPATABLET; ORAL
METHYLDOPA

AB	MYLAN	250MG		A070076	002	Apr 18, 1985	Apr	CMS1
----	-------	-------	--	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATEINJECTABLE; INJECTION
METHERGINE

AP	+ EDISON THERAPS LLC	0.2MG/ML		N006035	004		Feb	CAHN
AB	+ EDISON THERAPS LLC	0.2MG		N006035	003		Feb	CAHN

METHYLPHENIDATE HYDROCHLORIDETABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	CARACO	5MG	A090710	001	Mar 15, 2012	Jun	CAHN
>D>	AB		10MG	A090710	002	Mar 15, 2012	Jun	CAHN
>D>	AB		20MG	A090710	003	Mar 15, 2012	Jun	CAHN
	AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb	NEWA
	AB		10MG	A091159	002	Mar 12, 2014	Feb	NEWA
	AB		20MG	A091159	003	Mar 12, 2014	Feb	NEWA
>A>	AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun	CAHN
>A>	AB		10MG	A090710	002	Mar 15, 2012	Jun	CAHN
>A>	AB		20MG	A090710	003	Mar 15, 2012	Jun	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		METHYLPHENIDATE HYDROCHLORIDE						
		@ WATSON LABS	20MG	A040410	001	Feb 09, 2001	May	DISC

METRONIDAZOLEGEL; VAGINAL
METRONIDAZOLE

>D>		VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Jun	CAHN
			1.3%	N205223	001	Mar 24, 2014	Mar	NEWA
>A>		WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Jun	CAHN

TABLET; ORAL
METRONIDAZOLE

AB	UNICHEM LABS LTD	250MG		A203458	001	Jan 22, 2014	Jan	NEWA
AB		500MG		A203458	002	Jan 22, 2014	Jan	NEWA
	@ VIVIMED LABS	250MG		A070040	001	Jan 29, 1985	Apr	CAHN
	@	500MG		A070039	001	Jan 29, 1985	Apr	CAHN
	@ WATSON LABS	250MG		N018764	001	Sep 17, 1982	May	DISC
	@	500MG		N018764	002	Dec 20, 1982	May	DISC
AB	WATSON LABS INC	500MG		A070044	001	Feb 08, 1985	Mar	CAHN

MICONAZOLETABLET;BUCCAL
ORAVIG

+ BIOALLIANCE PHARMA 50MG N022404 001 Apr 16, 2010 Apr CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDEOINTMENT;TOPICAL
VUSION>A> + DELCOR ASSET 0.25%;81.35%;15% N021026 001 Feb 16, 2006 Jun CAHN
>D> + STIEFEL LABS INC 0.25%;81.35%;15% N021026 001 Feb 16, 2006 Jun CAHNMIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDEAP BEDFORD LABS EQ 1MG BASE/ML A075421 002 Jun 20, 2000 Apr CAHN
AP EQ 5MG BASE/ML A075421 001 Jun 20, 2000 Apr CAHNMILTEFOSINECAPSULE;ORAL
IMPAVIDO

PALADIN THERAP 50MG N204684 001 Mar 19, 2014 Mar NEWA

MINOCYCLINE HYDROCHLORIDECAPSULE;ORAL
DYNACINAB MEDICIS EQ 75MG BASE A063067 002 Sep 15, 1999 May CAHN
AB EQ 100MG BASE A063067 001 Jul 31, 1990 May CAHNMIRTAZAPINETABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE>A> @ ACTAVIS ELIZABETH 15MG A076689 001 Aug 31, 2005 Jun CAHN
>A> @ 30MG A076689 002 Aug 31, 2005 Jun CAHN
>A> @ 45MG A076689 003 Aug 31, 2005 Jun CAHN
>D> @ ACTAVIS TOTOWA 15MG A076689 001 Aug 31, 2005 Jun CAHN
>D> @ 30MG A076689 002 Aug 31, 2005 Jun CAHN
>D> @ 45MG A076689 003 Aug 31, 2005 Jun CAHNMIVACURIUM CHLORIDEINJECTABLE;INJECTION
MIVACURIUM CHLORIDE

@ AGILA SPECLTS EQ 2MG BASE/ML A078562 001 Apr 30, 2009 Feb CAHN

MODAFINILTABLET;ORAL
MODAFINILAB APOTEX INC 100MG A077667 001 Feb 03, 2014 Jan NEWA
AB 200MG A077667 002 Feb 03, 2014 Jan NEWAMOMETASONE FUROATEAEROSOL, METERED;INHALATION
ASMANEX HFAMERCK SHARP DOHME 0.10MG/INH N205641 001 Apr 25, 2014 Apr NEWA
+ 0.20MG/INH N205641 002 Apr 25, 2014 Apr NEWAPOWDER;INHALATION
ASMANEX TWISTHALERMERCK SHARP DOHME 0.11MG/INH N021067 002 Feb 01, 2008 Mar CAHN
+ 0.22MG/INH N021067 001 Mar 30, 2005 Mar CAHNMOMETASONE FUROATE MONOHYDRATESPRAY, METERED;NASAL
NASONEX

+ MERCK SHARP DOHME EQ 0.05MG BASE/SPRAY N020762 001 Oct 01, 1997 May CAHN

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
AVINZAAB2 KING PHARMS LLC 30MG N021260 001 Mar 20, 2002 Mar CAHN
AB2 45MG N021260 005 Dec 18, 2008 Mar CAHN
AB2 60MG N021260 002 Mar 20, 2002 Mar CAHN
AB2 75MG N021260 006 Dec 18, 2008 Mar CAHN

CAPSULE, EXTENDED RELEASE;ORAL
AVINZA

AB2		90MG	N021260	003	Mar 20, 2002	Mar	CAHN
AB2	+	120MG	N021260	004	Mar 20, 2002	Mar	CAHN

INJECTABLE; INJECTION
MORPHINE SULFATE

@	WATSON LABS	0.5MG/ML	A 073373	001	Sep 30, 1991	May	DISC
@		0.5MG/ML	A 073375	001	Sep 30, 1991	May	DISC
@		1MG/ML	A 073374	001	Sep 30, 1991	May	DISC
@		1MG/ML	A 073376	001	Sep 30, 1991	May	DISC

SOLUTION;ORAL
MORPHINE SULFATE

AA	CARACO	10MG/5ML	A 201011	001	Feb 05, 2014	Jan	NEWA
AA		20MG/5ML	A 201011	002	Feb 05, 2014	Jan	NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
EMBEDA

	ALPHARMA PHARMS	20MG;0.8MG	N 022321	001	Aug 13, 2009	Mar	CAHN
		30MG;1.2MG	N 022321	002	Aug 13, 2009	Mar	CAHN
		50MG;2MG	N 022321	003	Aug 13, 2009	Mar	CAHN
+		60MG;2.4MG	N 022321	004	Aug 13, 2009	Mar	CAHN
		80MG;3.2MG	N 022321	005	Aug 13, 2009	Mar	CAHN
		100MG;4MG	N 022321	006	Aug 13, 2009	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDETABLET;ORAL
AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N 021085	001	Dec 10, 1999	Feb	CFTG
			MOXIFLOXACIN HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A 202632	001	Mar 04, 2014	Feb	NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A 076938	001	Mar 04, 2014	Feb	NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A 077437	001	Feb 18, 2014	Feb	NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A 200160	001	Apr 03, 2014	Mar	NEWA

NAFCILLIN SODIUMINJECTABLE; INJECTION
NAFCILLIN SODIUM

AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A 200002	001	Apr 07, 2014	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A 200002	002	Apr 07, 2014	Mar	NEWA
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090560	001	Oct 03, 2011	Jan	CPOT
AP			EQ 2GM BASE/VIAL	A 090560	002	Oct 03, 2011	Jan	CPOT
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A 090002	001	Jun 30, 2011	Feb	CAHN
AP			EQ 2GM BASE/VIAL	A 090002	002	Jun 30, 2011	Feb	CAHN
AP			EQ 10GM BASE/VIAL	A 090005	001	Apr 20, 2011	Feb	CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A 204997	001	Mar 06, 2014	Feb	NEWA
			SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS					
			EVZIO					
+		KALEO INC	0.4MG/0.4ML	N 205787	001	Apr 03, 2014	Apr	NEWA

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

>D>		ALBALON							
>D>	AT	+	ALLERGAN	0.1%	A 080248	001		Jun	DISC
>A>		@		0.1%	A 080248	001		Jun	DISC
			NAPHAZOLINE HYDROCHLORIDE						
>D>	AT		AKORN INC	0.1%	A 083590	001		Jun	CRLD
>A>		+		0.1%	A 083590	001		Jun	CRLD

NAPROXENTABLET;ORAL
NAPROXEN

@	DAVA PHARMS INC	250MG	A 074410	001	Apr 28, 1995	Feb	DISC
@		375MG	A 074410	002	Apr 28, 1995	Feb	DISC
@		500MG	A 074410	003	Apr 28, 1995	Feb	DISC
@	WATSON LABS	250MG	A 074457	001	May 31, 1995	May	DISC
@		375MG	A 074457	002	May 31, 1995	May	DISC
@		500MG	A 074457	003	May 31, 1995	May	DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ WATSON LABS

EQ 250MG BASE

A 074455 001 May 31, 1995 May DISC

@

EQ 500MG BASE

A 074455 002 May 31, 1995 May DISC

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB APOTEX CORP

EQ 1MG BASE

A 091373 001 Apr 22, 2011 Jan CAHN

AB

EQ 2.5MG BASE

A 091373 002 Apr 22, 2011 Jan CAHN

AB SUN PHARM INDS LTD

EQ 2.5MG BASE

A 091552 001 Feb 14, 2011 Jan CAHN

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB STRIDES ARCOLAB LTD 200MG

A 078195 001 May 22, 2012 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB APOTEX INC 400MG

A 205258 001 Apr 03, 2014 Mar NEWA

AB SANDOZ 400MG

A 203411 001 Apr 03, 2014 Mar NEWA

VIRAMUNE XR

AB + BOEHRINGER INGELHEIM 400MG

N 201152 001 Mar 25, 2011 Mar CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB LUPIN LTD 1GM

A 090446 001 Mar 20, 2014 Mar NEWA

AB 500MG

A 090860 001 Mar 20, 2014 Mar NEWA

AB 750MG

A 090892 001 Mar 20, 2014 Mar NEWA

AB SUN PHARMA GLOBAL 1GM

A 200484 002 Apr 23, 2014 Apr NEWA

AB 500MG

A 200484 001 Apr 23, 2014 Apr NEWA

AB 750MG

A 201273 001 Apr 23, 2014 Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

AB CHIESI USA INC 20MG

N 019488 001 Dec 21, 1988 Apr CAHN

AB + 30MG

N 019488 002 Dec 21, 1988 Apr CAHN

NICARDIPINE HYDROCHLORIDE

AB ANI PHARMS INC 20MG

A 074439 001 Dec 10, 1996 Jan CAHN

AB 20MG

A 074540 001 Oct 28, 1996 Jan CAHN

AB 30MG

A 074439 002 Dec 10, 1996 Jan CAHN

AB 30MG

A 074540 002 Oct 28, 1996 Jan CAHN

@ WATSON LABS 20MG

A 074670 001 Oct 28, 1996 May DISC

@ 30MG

A 074670 002 Oct 28, 1996 May DISC

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

+ CHIESI USA INC 30MG

N 020005 001 Feb 21, 1992 Apr CAHN

@ 45MG

N 020005 002 Feb 21, 1992 Apr CAHN

+ 60MG

N 020005 003 Feb 21, 1992 Apr CAHN

INJECTABLE; INJECTION

CARDENE

AP + CHIESI USA INC 25MG/10ML (2.5MG/ML)

N 019734 001 Jan 30, 1992 Apr CAHN

NICARDIPINE HYDROCHLORIDE

AP LUITPOLD 25MG/10ML (2.5MG/ML)

A 090534 001 Nov 17, 2009 Jan CAHN

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC 40MG/200ML (0.2MG/ML)

N 019734 004 Nov 07, 2008 Apr CAHN

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC 20MG/200ML (0.1MG/ML)

N 019734 003 Jul 31, 2008 Apr CAHN

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC 20MG/200ML (0.1MG/ML)

N 019734 002 Jul 31, 2008 Apr CAHN

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC 40MG/200ML (0.2MG/ML)

N 019734 005 Nov 07, 2008 Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITROGLYCERIN

@ KREMERS URBAN PHARMS 0.2MG/HR
@ 0.4MG/HR

A075115	001	Aug 10, 2004	May	DISC
A075115	002	Aug 10, 2004	May	DISC

OINTMENT;INTRA-ANAL
RECTIV

+ FOREST LABS INC 0.4%

N021359	001	Jun 21, 2011	Apr	CAHN
---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE;ORAL
NIZATIDINE

@ ANI PHARMS INC 150MG

A075461	001	Jul 08, 2002	Jan	CAHN
---------	-----	--------------	-----	------

AB		150MG	A075668	001	Sep 12, 2002	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

@ 300MG

A075461	002	Jul 08, 2002	Jan	CAHN
---------	-----	--------------	-----	------

AB		300MG	A075668	002	Sep 12, 2002	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION;ORAL

AVENTYL

@ RANBAXY EQ 10MG BASE/5ML

N014685	001		Apr	CTNA
---------	-----	--	-----	------

AVENTYL HYDROCHLORIDE

@ RANBAXY EQ 10MG BASE/5ML

N014685	001		Apr	DISC
---------	-----	--	-----	------

NORTRIPTYLINE HYDROCHLORIDE

AA	+ PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr	CRLD
----	---------------	------------------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A203708	002	May 15, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A203708	003	May 15, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A203708	004	May 15, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr	NEWA
----	------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A202285	002	May 12, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A202285	003	May 12, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A202285	004	May 12, 2014	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+ SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
----	----------------------	--	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

>A>	AB	PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGS-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun	NEWA
-----	----	---------------	--	---------	-----	--------------	-----	------

AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
----	-----------------	--	---------	-----	--------------	-----	------

OMTRYG

+ TRYGG 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977	001	Apr 23, 2014	Apr	NEWA
---------	-----	--------------	-----	------

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May NEWA
---	--------------------	--	---------	-----	--------------	----------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID

AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN

FOR SUSPENSION;ORAL

>D> OMEPRAZOLE AND SODIUM BICARBONATE

>D>	AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
>A>		@	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
>D>	AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC
>A>		@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC

ZEGERID

>D>	AB	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>D>	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
>A>			20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
>D>	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
>A>	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

@ LANNETT

EQ 2MG BASE/ML

A090116 001 Apr 14, 2010 Jan DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

@ WATSON LABS

30MG/ML

A087062 001 May DISC

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

@ ISTITUTO BIO ITA SPA

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995 Feb CAHN

@

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995 Feb CAHN

@

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995 Feb CAHN

@

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995 Feb CAHN

@

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995 Feb CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

>A>	AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Jun NEWA
>A>	AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Jun NEWA
	AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar NEWA
	AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar NEWA

OXANDROLONE

TABLET; ORAL

OXANDRIN

AB		CREALTA PHARMS LLC	2.5MG		N013718	001			Jan	CAHN
AB	+		10MG		N013718	002	Nov 05, 2001		Jan	CAHN

OXAPROZIN

TABLET; ORAL

OXAPROZIN

		@ WATSON LABS	600MG		A075848	001	Feb 09, 2001		May	DISC
--	--	---------------	-------	--	---------	-----	--------------	--	-----	------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

		@ IVAX SUB TEVA PHARMS	10MG		A070943	001	Aug 03, 1987		Apr	DISC
		@	15MG		A070944	001	Aug 03, 1987		Apr	DISC
		@	30MG		A070945	001	Aug 03, 1987		Apr	DISC
		@ WATSON LABS	10MG		A072952	001	Sep 28, 1990		May	DISC
		@	15MG		A072953	001	Sep 28, 1990		May	DISC
		@	30MG		A072954	001	Sep 28, 1990		May	DISC

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

		@ ANI PHARMS INC	150MG		A078005	001	Dec 11, 2007		Jan	CAHN
		@	300MG		A078005	002	Dec 11, 2007		Jan	CAHN
		@	600MG		A078005	003	Dec 11, 2007		Jan	CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYBUTYNIN

AB		BARR LABS DIV TEVA	3.9MG/24HR		A090526	001	Mar 04, 2014		Feb	NEWA
AB	+	WATSON LABS (UTAH)	3.9MG/24HR		N021351	002	Feb 26, 2003		Feb	CFTG

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA		COASTAL PHARMS	100MG/5ML		A204092	001	Jun 05, 2014		May	NEWA
>A>	AA	LEHIGH VALLEY	5MG/5ML		N200535	002	Aug 22, 2013		Jun	NEWA

TABLET; ORAL

OXECTA

		ACURA PHARMS INC	5MG		N202080	001	Jun 17, 2011		May	CAHN
			7.5MG		N202080	002	Jun 17, 2011		May	CAHN

OXYCODONE HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG		A203638	001	Jun 03, 2014		May	NEWA
AB			10MG		A203638	002	Jun 03, 2014		May	NEWA
AB			15MG		A203638	003	Jun 03, 2014		May	NEWA
AB			20MG		A203638	004	Jun 03, 2014		May	NEWA
AB			30MG		A203638	005	Jun 03, 2014		May	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

>A>	AB	MALLINCKRODT INC	5MG		A202946	001	Jun 27, 2014		Jun	NEWA
>A>	AB		7.5MG		A202946	002	Jun 27, 2014		Jun	NEWA
>A>	AB		10MG		A202946	003	Jun 27, 2014		Jun	NEWA
>A>	AB		15MG		A202946	004	Jun 27, 2014		Jun	NEWA
>A>	AB		20MG		A202946	005	Jun 27, 2014		Jun	NEWA
>A>	AB		30MG		A202946	006	Jun 27, 2014		Jun	NEWA
>A>	AB		40MG		A202946	007	Jun 27, 2014		Jun	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+	HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)		N018243	001			May	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)		N018243	002	Jan 10, 2007		May	CAHN
		PITOCIN								
AP	+	PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)		N018261	001			Apr	CAHN
AP			100USP UNITS/10ML (10USP UNITS/ML)		N018261	002	Jul 27, 2007		Apr	CAHN
			500USP UNITS/50ML (10USP UNITS/ML)		N018261	003	Sep 05, 2012		Apr	CAHN

SOLUTION;NASAL
SYNTOCINON

@	RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb	CAHN
---	---------------	----------------	---------	-----	--	-----	------

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

>D>	AP	MYLAN	6MG/ML	A075278	001	Jan 25, 2002	Jun	DISC
>A>		@	6MG/ML	A075278	001	Jan 25, 2002	Jun	DISC

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

@	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan	DISC
@		90MG/VIAL	A078300	002	Mar 10, 2009	Jan	DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PANCREAZE

>A>		JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014	Jun	NEWA
-----	--	----------------	---	---------	-----	--------------	-----	------

ULTRESA

		FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	May	CAHN
			41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	May	CAHN
+			46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	May	CAHN

ZENPEP

		APTALIS PHARMA US	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar	NEWA
		FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Apr	CAHN
			16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr	CAHN
			55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009	Apr	CAHN
			82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009	Apr	CAHN
			27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009	Apr	CAHN
			109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr	CAHN
+			136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr	CAHN

TABLET;ORAL

VIOKACE

		FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr	CAHN
+			78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr	CAHN
		FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	CAHN
+			78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr	NEWA
----	--	-----------------	--------------	---------	-----	--------------	-----	------

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

>A>	AB	ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Jun	NEWA
>A>	AB		2MCG	A202124	002	Jun 24, 2014	Jun	NEWA
>A>	AB		4MCG	A202124	003	Jun 24, 2014	Jun	NEWA
	AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar	NEWA
	AB		2MCG	A202539	002	Mar 27, 2014	Mar	NEWA
	AB		4MCG	A202539	003	Mar 27, 2014	Mar	NEWA
>A>	AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun	NEWA
>A>	AB		2MCG	A091412	002	Jun 24, 2014	Jun	NEWA
>A>	AB		4MCG	A091412	003	Jun 24, 2014	Jun	NEWA

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN
@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN
@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN
@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN

SUSPENSION;ORAL

PAXIL

AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
----	---	---------------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

PAXIL

AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan	CAHN
AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan	CAHN
AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan	CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan	CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb	CAHN
AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb	CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb	CAHN

>D> PEMIROLAST POTASSIUM

>D> SOLUTION/DROPS;OPHTHALMIC

>D> ALAMAST

>D>	+	SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun	DISC
>A>	@		0.1%	N021079	001	Sep 24, 1999	Jun	DISC

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr	CAHN
+		20MG	N018976	004	Jan 05, 1989	Apr	CAHN

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

AP		ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb	CAHN
AP			20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb	CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAM

+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May	CTEC
@	WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May	DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

@	WATSON LABS	400MG	A075107	001	Sep 04, 1998	May	DISC
	TRENTAL						

>D>	AB	+	SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984	Jun	DISC
>A>		@		400MG	N018631	001	Aug 30, 1984	Jun	DISC

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB		ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan	CAHN
AB			4MG	A078138	002	Nov 10, 2009	Jan	CAHN
AB			8MG	A078138	003	Nov 10, 2009	Jan	CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

@	ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr	CAHN
@	TEVA PHARMS USA	2MG	A089707	001	Sep 10, 1987	Apr	CAHN
@		4MG	A089708	001	Sep 10, 1987	Apr	CAHN
@		16MG	A089457	001	Sep 10, 1987	Apr	CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr	CAHN
----	----------------	------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb	NEWA
AA		30MG	A202858	002	Feb 14, 2014	Feb	NEWA
AA		30MG	A204414	001	May 05, 2014	Apr	NEWA
AA		37.5MG	A202846	001	Feb 05, 2014	Jan	NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan	NEWA
AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May	CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

VAZCULEP

>A>							
>A>	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun	NEWA
>A>		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun	NEWA
>A>	+	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun	NEWA

PHENYTOIN

TABLET, CHEWABLE; ORAL

PHENYTOIN

AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr	NEWA
----	------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

@ ANI PHARMS INC

100MG EXTENDED

A040435 001 Jun 20, 2003 Apr CAHN

@

100MG EXTENDED

A089441 001 Dec 18, 1986 Jan CAHN

PROMPT PHENYTOIN SODIUM

@ ANI PHARMS INC

100MG PROMPT

A080259 001 Jan CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb	CMFD
AB		10MG	A074063	002	Jan 27, 1994	Feb	CMFD
AB	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb	CTEC
AB	+	10MG	A074019	002	Sep 03, 1992	Feb	CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar	NEWA
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar	NEWA
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+ ISTITUTO BIO ITA SPA

EQ 2GM BASE/VIAL

A065114 001 Nov 14, 2003 Feb CAHN

+

EQ 3GM BASE/VIAL

A065114 002 Nov 14, 2003 Feb CAHN

+

EQ 4GM BASE/VIAL

A065114 003 Nov 14, 2003 Feb CAHN

+

EQ 40GM BASE/VIAL

A065157 001 Jul 12, 2004 Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb	CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb	CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb	CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ WATSON LABS	10MG	A 074287	001	May 16, 1996	May DISC
@	10MG	A 074460	001	Sep 29, 1995	May DISC
@	20MG	A 074287	002	May 16, 1996	May DISC
@	20MG	A 074460	002	Sep 29, 1995	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

CO-LAV

@ VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A 073428	001	Jan 28, 1992	Feb CAHN
------------------	--	----------	-----	--------------	----------

GO-EVAC

@ VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A 073433	001	Apr 28, 1992	Feb CAHN
------------------	--	----------	-----	--------------	----------

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

+ CHIESI USA INC	80MG/ML	N 020744	001	Nov 18, 1999	Apr CAHN
------------------	---------	----------	-----	--------------	----------

POSACONAZOLE

SOLUTION; IV (INFUSION)

NOXAFIL

+ MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N 205596	001	Mar 13, 2014	Mar NEWA
---------------------	------------------------	----------	-----	--------------	----------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ INTL MEDICATION	2MEQ/ML	A 083163	001		Mar DISC
-------------------	---------	----------	-----	--	----------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	STRIDES ARCOLAB LTD	0.125MG	A 202702	001	Jun 03, 2014	May NEWA
AB		0.25MG	A 202702	002	Jun 03, 2014	May NEWA
AB		0.5MG	A 202702	003	Jun 03, 2014	May NEWA
AB		0.75MG	A 202702	004	Jun 03, 2014	May NEWA
AB		1MG	A 202702	005	Jun 03, 2014	May NEWA
AB		1.5MG	A 202702	006	Jun 03, 2014	May NEWA

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N 022421	001	Feb 19, 2010	Jan CFTG
AB		0.75MG	N 022421	002	Feb 19, 2010	Jan CFTG
AB		1.5MG	N 022421	003	Feb 19, 2010	Jan CFTG
AB		2.25MG	N 022421	006	Jun 17, 2011	Jan CFTG
AB		3MG	N 022421	004	Feb 19, 2010	Jan CFTG
AB		3.75MG	N 022421	007	Jun 17, 2011	Jan CFTG
AB		4.5MG	N 022421	005	Feb 19, 2010	Jan CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A 202206	001	Feb 06, 2014	Jan NEWA
AB		0.75MG	A 202206	002	Feb 06, 2014	Jan NEWA
AB		1.5MG	A 202206	003	Feb 06, 2014	Jan NEWA
AB		2.25MG	A 202206	004	Feb 06, 2014	Jan NEWA
AB		3MG	A 202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG	A 202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A 202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N 021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N 021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N 021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr	CMFD
AB		20MG	A076397	002	Oct 23, 2006	Apr	CMFD
AB		40MG	A076397	001	Oct 23, 2006	Apr	CMFD

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+ BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CRLD
	VASOCIDIN						
	@ NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb	DISC

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

AB	+ SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan	CFTG
	PRIMAQUINE PHOSPHATE						
AB	ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan	NEWA
AB	BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb	NEWA

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@ ANI PHARMS INC

1GM

A040111 001 Dec 13, 1996 Jan CAHN

@

250MG

A088958 001 Dec 02, 1985 Jan CAHN

@

500MG

A088959 001 Dec 02, 1985 Jan CAHN

@

500MG

A088974 001 Jul 22, 1985 Mar CAHN

@

750MG

A089438 001 Mar 23, 1987 Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

@ DELCOR ASSET CORP

50MG

N011689 001 Apr CAHN

TABLET; ORAL

PHENERGAN

@ DELCOR ASSET CORP

12.5MG

N007935 002 Apr CAHN

@

25MG

N007935 003 Apr CAHN

@

50MG

N007935 004 Apr CAHN

@ SHIONOGI INC

12.5MG

N007935 002 May CAHN

@

25MG

N007935 003 May CAHN

@

50MG

N007935 004 May CAHN

PROMETHAZINE HYDROCHLORIDE

>D>	AB	CARACO	12.5MG	A040863	001	Dec 30, 2008	Jun	CAHN
>D>	AB		25MG	A040863	002	Dec 30, 2008	Jun	CAHN
>D>	AB		50MG	A040863	003	Dec 30, 2008	Jun	CAHN
	AB	SANDOZ	25MG	A084176	003		Apr	CMS1
>A>	AB	SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun	CAHN
>A>	AB		25MG	A040863	002	Dec 30, 2008	Jun	CAHN
>A>	AB		50MG	A040863	003	Dec 30, 2008	Jun	CAHN

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB ANI PHARMS INC

150MG

A076550 001 Apr 23, 2004 Jan CAHN

AB

225MG

A076550 002 Apr 23, 2004 Jan CAHN

AB

300MG

A076550 003 Apr 23, 2004 Jan CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

>D>	AT	ALCON	0.5%	A080027	001		Jun	CRLD
>A>	AT	+ ALCON	0.5%	A080027	001		Jun	CRLD
>D>		OPHTHAINE						
>D>	AT	+ APOTHECON	0.5%	N008883	001		Jun	DISC
>A>		@	0.5%	N008883	001		Jun	DISC
>D>		OPHTHETIC						
>D>	AT	+ ALLERGAN	0.5%	N012583	001		Jun	DISC
>A>		@	0.5%	N012583	001		Jun	DISC

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

HEMANGEOL

+ PIERRE FABRE DERMA 4.28MG/ML N205410 001 Mar 14, 2014 Mar NEWA

TABLET; ORAL

INDERAL

@ WYETH PHARMS INC 40MG N016418 002 Jan DISC

@ 60MG N016418 009 Oct 18, 1982 Jan DISC

@ 80MG N016418 004 Jan DISC

PROPRANOLOL HYDROCHLORIDE

@ ANI PHARMS INC 90MG A071977 001 Apr 06, 1988 Jan CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

@ ANI PHARMS INC 50MG A080215 001 Jan CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@ WATSON LABS 324MG A087810 001 Sep 29, 1982 May DISC

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

AB + LILLY 60MG N020815 001 Dec 09, 1997 Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB TEVA PHARMS USA 60MG A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC 1.25MG A202392 001 Apr 15, 2014 Mar NEWA

AB 2.5MG A202392 002 Apr 15, 2014 Mar NEWA

AB 5MG A202392 003 Apr 15, 2014 Mar NEWA

AB 10MG A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP + COVIS INJECTABLES EQ 25MG BASE/ML N019090 001 Oct 19, 1984 Apr CAHN

ZANTAC IN PLASTIC CONTAINER

@ COVIS INJECTABLES EQ 1MG BASE/ML N019593 002 Sep 27, 1991 Apr CAHN

@ EQ 50MG BASE/100ML N019593 001 Dec 17, 1986 Apr CAHN

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

@ GLAXO GRP LTD EQ 25MG BASE N020251 003 Apr 01, 2004 Feb DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC EQ 0.5MG BASE A201823 001 Jul 01, 2013 May DISC

@ EQ 1MG BASE A201823 002 Jul 01, 2013 May DISC

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB ACTAVIS TOTOWA 0.5MG A090008 001 Jan 22, 2014 Jan NEWA

AB 1MG A090008 002 Jan 22, 2014 Jan NEWA

AB 2MG A090008 003 Jan 22, 2014 Jan NEWA

AB AUROBINDO PHARMA LTD 0.5MG A203820 001 Jan 22, 2014 Jan NEWA

AB 1MG A203820 002 Jan 22, 2014 Jan NEWA

AB 2MG A203820 003 Jan 22, 2014 Jan NEWA

AB MYLAN PHARMS INC 1MG A090252 002 Jan 22, 2014 Jan NEWA

AB 2MG A090252 003 Jan 22, 2014 Jan NEWA

AB PADDOCK LLC 1MG A201189 002 Jan 22, 2014 Jan NEWA

AB 2MG A201189 003 Jan 22, 2014 Jan NEWA

AB SANDOZ 1MG A078555 002 Jan 22, 2014 Jan NEWA

AB 2MG A078555 003 Jan 22, 2014 Jan NEWA

RIFABUTIN

CAPSULE;ORAL		MYCOBUTIN	
AB	+ PHARMACIA AND UPJOHN	150MG	N050689 001 Dec 23, 1992 Feb CFTG
AB	LUPIN LTD	150MG	A090033 001 Feb 24, 2014 Feb NEWA

RISEDRONATE SODIUM

TABLET;ORAL		ACTONEL	
AB	+ WARNER CHILCOTT LLC	150MG	N020835 005 Apr 22, 2008 May CTEC
AB	APOTEX INC	75MG	A090877 002 Jun 10, 2014 May NEWA
AB		150MG	A090877 003 Jun 10, 2014 May NEWA
AB	MYLAN PHARMS INC	75MG	A200477 004 Jun 10, 2014 May NEWA
AB		150MG	A200477 005 Jun 10, 2014 May NEWA
AB	SUN PHARMA GLOBAL	75MG	A090886 004 Jun 10, 2014 May NEWA
AB		150MG	A090886 005 Jun 10, 2014 May NEWA
>A>	AB TEVA PHARMS USA	150MG	A079215 001 Jun 13, 2014 Jun NEWA

RISPERIDONE

SOLUTION;ORAL		RISPERIDONE	
AA	ANI PHARMS INC	1MG/ML	A076440 001 Jan 30, 2009 Jan CAHN
TABLET;ORAL		RISPERIDONE	
AB	CARACO	0.25MG	A078036 001 Mar 10, 2014 Feb NEWA
AB		0.5MG	A078036 002 Mar 10, 2014 Feb NEWA
AB		1MG	A078036 003 Mar 10, 2014 Feb NEWA
AB		2MG	A078036 004 Mar 10, 2014 Feb NEWA
AB		3MG	A078036 005 Mar 10, 2014 Feb NEWA
AB		4MG	A078036 006 Mar 10, 2014 Feb NEWA

RIVASTIGMINE TARTRATE

>D>	SOLUTION;ORAL		
>D>	EXELON		
>D>	+ NOVARTIS	EQ 2MG BASE/ML	N021025 001 Apr 21, 2000 Jun DISC
>A>	@	EQ 2MG BASE/ML	N021025 001 Apr 21, 2000 Jun DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL		RIZATRIPTAN BENZOATE	
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147 001 Feb 11, 2014 Jan NEWA
AB		EQ 10MG BASE	A203147 002 Feb 11, 2014 Jan NEWA

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL		ONGLYZA	
	ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001 Jul 31, 2009 May CAHN
	+	EQ 5MG BASE	N022350 002 Jul 31, 2009 May CAHN

SIMEPREVIR SODIUM

CAPSULE;ORAL		OLYSIO	
>A>	+ JANSSEN PRODS	EQ 150MG BASE	N205123 001 Nov 22, 2013 Jun CAHN
>D>	+ JANSSEN RES AND DEV	EQ 150MG BASE	N205123 001 Nov 22, 2013 Jun CAHN
	+	EQ 150MG BASE	N205123 001 Nov 22, 2013 Feb CAIN

SODIUM CHLORIDE

INJECTABLE;INJECTION		SODIUM CHLORIDE 0.9%	
>D>	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832 002 Jan 06, 2012 Jun DISC
>A>	@	18MG/2ML (9MG/ML)	N202832 002 Jan 06, 2012 Jun DISC
>D>		22.5MG/2.5ML (9MG/ML)	N202832 003 Jan 06, 2012 Jun DISC
>A>	@	22.5MG/2.5ML (9MG/ML)	N202832 003 Jan 06, 2012 Jun DISC
>D>		27MG/3ML (9MG/ML)	N202832 004 Jan 06, 2012 Jun DISC
>A>	@	27MG/3ML (9MG/ML)	N202832 004 Jan 06, 2012 Jun DISC
>D>		45MG/5ML (9MG/ML)	N202832 005 Jan 06, 2012 Jun DISC
>A>	@	45MG/5ML (9MG/ML)	N202832 005 Jan 06, 2012 Jun DISC
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
>D>	MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001 Jan 06, 2012 Jun DISC

	INJECTABLE; INJECTION								
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
>A>	@	9MG/ML (9MG/ML)		N202832	001	Jan 06, 2012		Jun	DISC
	<u>SODIUM FLUORIDE F-18</u>								
	INJECTABLE; INTRAVENOUS								
	SODIUM FLUORIDE F-18								
AP	UCSF RODIOPHARM	10-200mCi/ML		A204437	001	Mar 13, 2014		Mar	NEWA
	<u>SODIUM POLYSTYRENE SULFONATE</u>								
	POWDER; ORAL, RECTAL								
	SODIUM POLYSTYRENE SULFONATE								
AA	EPIC PHARMA LLC	453.6GM/BOT		A202333	001	Mar 19, 2014		Mar	NEWA
	<u>SOLIFENACIN SUCCINATE</u>								
	TABLET; ORAL								
	SOLIFENACIN SUCCINATE								
AB	TEVA PHARMS USA	5MG		A091464	001	Apr 02, 2014		Mar	NEWA
AB		10MG		A091464	002	Apr 02, 2014		Mar	NEWA
	VESICARE								
AB	ASTELLAS	5MG		N021518	001	Nov 19, 2004		Mar	CFTG
AB	+	10MG		N021518	002	Nov 19, 2004		Mar	CFTG
	<u>SOMATROPIN RECOMBINANT</u>								
	INJECTABLE; INJECTION								
	ACCRETROPIN								
	@ EMERGENT	5MG/ML (5MG/ML)		N021538	001	Jan 23, 2008		Feb	CAHN
	<u>SPIRONOLACTONE</u>								
	TABLET; ORAL								
	SPIRONOLACTONE								
AB	JUBILANT LIFE	25MG		A203253	001	Apr 23, 2014		Apr	NEWA
AB		50MG		A203253	002	Apr 23, 2014		Apr	NEWA
AB		100MG		A203253	003	Apr 23, 2014		Apr	NEWA
AB	ORION CORP ORION	25MG		A202187	001	Mar 06, 2014		Feb	NEWA
AB		50MG		A202187	002	Mar 06, 2014		Feb	NEWA
AB		100MG		A202187	003	Mar 06, 2014		Feb	NEWA
	<u>SUCRALFATE</u>								
	SUSPENSION; ORAL								
	CARAFATE								
	+ FOREST LABS INC	1GM/10ML		N019183	001	Dec 16, 1993		Apr	CAHN
	TABLET; ORAL								
	CARAFATE								
AB	+ FOREST LABS INC	1GM		N018333	001			Apr	CAHN
	<u>SULFASALAZINE</u>								
	TABLET; ORAL								
	SULFASALAZINE								
	@ WATSON LABS	500MG		A087197	001			May	DISC
	<u>SUMATRIPTAN SUCCINATE</u>								
	INJECTABLE; SUBCUTANEOUS								
	IMITREX STATDOSE								
BX	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N020080	002	Feb 01, 2006		May	CTEC
	SUMATRIPTAN SUCCINATE								
AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A203322	001	Apr 14, 2014		Mar	NEWA
AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090495	001	Jan 29, 2014		Jan	NEWA
>D>	AP	JHP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009		Jun	CAHN
>A>	AP	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009		Jun	CAHN
	SUMAVEL DOSEPRO								
BX	+ ZOGENIX INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013		May	NEWA
	SYSTEM; IONTOPHORESIS								
	ZECUITY								
	+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR		N202278	001	Jan 17, 2013		May	CAHN

SUNITINIB MALATE

CAPSULE;ORAL		SUNITINIB MALATE					
AB	MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan	NEWA
AB		EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan	NEWA
AB		EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan	NEWA
AB		EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan	NEWA
SUTENT							
AB	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan	CFTG
AB		EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan	CFTG
AB		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan	CFTG
AB	+	EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan	CFTG

TACROLIMUS

CAPSULE;ORAL		TACROLIMUS					
	@ WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	May	DISC

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC		ZIOPTAN					
+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr	CAHN

TASIMELTEON

CAPSULE;ORAL		HETLIOZ					
+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan	NEWA

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL		TECHNELITE					
	@ LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May	DISC
	ULTRA-TECHNEKOW FM						
	@ MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		May	DISC
SOLUTION;INTRAVENOUS		TECHNELITE					
+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	May	NEWA
	@	0.0083-2.7 CI/GENERATOR	N017771	001		May	CDFR
	ULTRA-TECHNEKOW FM						
+	MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	May	NEWA
	@	0.25-3 CI/GENERATOR	N017243	002		May	CDFR
SOLUTION;INTRAVENOUS, ORAL		TECHNETIUM TC 99M GENERATOR					
+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	May	NEWA
		830-16600mCi/GENERATOR	N017693	001		May	CDFR

>A> <u>TEDIZOLID PHOSPHATE</u>								
POWDER;IV (INFUSION)		SIVEXTRO						
>A>	+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Jun	NEWA
TABLET;ORAL		SIVEXTRO						
>A>	+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Jun	NEWA

TELAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)		VIBATIV						
>A>		THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jun	CAHN
>A>	+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jun	CAHN
>D>		THERAVANCE INC	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jun	CAHN
>D>	+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jun	CAHN

TELMISARTAN

TABLET;ORAL		TELMISARTAN						
>A>	AB	ALEMBIC PHARMS LTD	20MG	A202130	001	Jul 07, 2014	Jun	NEWA
>A>	AB		40MG	A202130	002	Jul 07, 2014	Jun	NEWA
>A>	AB		80MG	A202130	003	Jul 07, 2014	Jun	NEWA
>A>	AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	Jun	NEWA
>A>	AB		40MG	A090032	002	Jul 07, 2014	Jun	NEWA
>A>	AB		80MG	A090032	003	Jul 07, 2014	Jun	NEWA

TABLET;ORAL

TELMISARTAN

>A>	AB	MYLAN PHARMS INC	20MG	A202397	001	Jul 07, 2014	Jun	NEWA
>A>	AB		40MG	A202397	002	Jul 07, 2014	Jun	NEWA
>A>	AB		80MG	A202397	003	Jul 07, 2014	Jun	NEWA
>A>	AB	TORRENT PHARMS LTD	20MG	A203171	001	Jul 07, 2014	Jun	NEWA
>A>	AB		40MG	A203171	002	Jul 07, 2014	Jun	NEWA
>A>	AB		80MG	A203171	003	Jul 07, 2014	Jun	NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

@	WATSON LABS	15MG	A071446	001	May 21, 1993	May	DISC
@		30MG	A071447	001	May 21, 1993	May	DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb	NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb	NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb	NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb	NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb	NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

HYTRIN

@	ABBOTT	EQ 1MG BASE	N020347	001	Dec 14, 1994	Apr	DISC
@		EQ 2MG BASE	N020347	002	Dec 14, 1994	Apr	DISC
@		EQ 5MG BASE	N020347	003	Dec 14, 1994	Apr	DISC
@		EQ 10MG BASE	N020347	004	Dec 14, 1994	Apr	DISC

TERAZOSIN HYDROCHLORIDE

AB	+	SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr	CRLD
----	---	--------	-------------	---------	-----	--------------	-----	------

TABLET;ORAL

HYTRIN

@	ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987	Apr	DISC
@		EQ 2MG BASE	N019057	002	Aug 07, 1987	Apr	DISC
@		EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr	DISC
@		EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr	DISC

TESAMORELIN ACETATE

POWDER;SUBCUTANEOUS

EGRIFTA

@	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May	CAHN

TESTOSTERONE

GEL;TRANSDERMAL

VOGELXO

>A>		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	NEWA
-----	--	--------------	-----------------	---------	-----	--------------	-----	------

>D> GEL, METERED;NASAL

>D> NATESTO

>D>	+	TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	DISC
>A>	@		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	DISC
	+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May	NEWA

GEL, METERED;TRANSDERMAL

VOGELXO

>A>		UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	NEWA
-----	--	--------------	-------------------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Apr	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

TESTOSTERONE UNDECANOATE

INJECTABLE;INTRAMUSCULAR

AVEED

+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

THEOPHYLLINE

>D>	ELIXIR;ORAL						
>D>	ELIXOPHYLLIN						
>D>	+ CARACO	80MG/15ML	A 085186	001			Jun CDFR
>A>	SOLUTION, ELIXIR;ORAL						
>A>	ELIXOPHYLLIN						
>A>	+ CARACO	80MG/15ML	A 085186	001			Jun CDFR
	TABLET, EXTENDED RELEASE;ORAL						
	THEOCHRON						
	@ CARACO	300MG	A 087400	002	Jan 11, 1983		Jan DISC

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	THIAMINE HYDROCHLORIDE						
	@ WATSON LABS	100MG/ML	A 080571	001			May DISC
	@	200MG/ML	A 080571	002			May DISC

THIORIDAZINE HYDROCHLORIDE

	CONCENTRATE;ORAL						
	THIORIDAZINE HYDROCHLORIDE						
	@ ANI PHARMS INC	100MG/ML	A 089603	001	Nov 09, 1987		Feb CAHN
	TABLET;ORAL						
	THIORIDAZINE HYDROCHLORIDE						
	@ ANI PHARMS INC	10MG	A 088270	001	Apr 14, 1983		Feb CAHN
	@	10MG	A 088493	001	May 17, 1985		Feb CAHN
	@	15MG	A 088271	001	Apr 14, 1983		Feb CAHN
	@	25MG	A 088272	001	Apr 14, 1983		Feb CAHN
	@	50MG	A 088194	001	Apr 14, 1983		Feb CAHN
	@	100MG	A 088273	001	Oct 03, 1983		Feb CAHN
	@	100MG	A 088456	001	May 17, 1985		Feb CAHN

THIOTHIXENE

	CAPSULE;ORAL						
	THIOTHIXENE						
	@ WATSON LABS	2MG	A 070601	001	Jun 05, 1987		May DISC
	@	5MG	A 070602	001	Jun 05, 1987		May DISC

TIMOLOL

	SOLUTION/DROPS;OPHTHALMIC						
	BETIMOL						
	+ OAK PHARMS AKORN	EQ 0.25% BASE	N 020439	001	Mar 31, 1995		Apr CAHN
	+	EQ 0.5% BASE	N 020439	002	Mar 31, 1995		Apr CAHN

TOBRAMYCIN

	SOLUTION; INHALATION						
	BETHKIS						
	CHIESI USA INC	300MG/4ML	N 201820	001	Oct 12, 2012		Apr CAHN
	TOBRAMYCIN						
AN	AKORN INC	300MG/5ML	A 201422	001	May 28, 2014		May NEWA

TOBRAMYCIN SULFATE

	INJECTABLE; INJECTION						
	TOBRAMYCIN SULFATE						
	@ WATSON LABS INC	EQ 10MG BASE/ML	A 062945	001	Aug 09, 1989		May DISC

TOPIRAMATE

	CAPSULE, DELAYED RELEASE;ORAL						
	QUDEXY XR						
	UPSHER SMITH	25MG	N 205122	001	Mar 11, 2014		Mar NEWA
		50MG	N 205122	002	Mar 11, 2014		Mar NEWA
		100MG	N 205122	003	Mar 11, 2014		Mar NEWA
		150MG	N 205122	004	Mar 11, 2014		Mar NEWA
	+	200MG	N 205122	005	Mar 11, 2014		Mar NEWA
	CAPSULE, EXTENDED RELEASE;ORAL						
	QUDEXY XR						
	UPSHER SMITH	25MG	N 205122	001	Mar 11, 2014		Apr CDFR
		50MG	N 205122	002	Mar 11, 2014		Apr CDFR
		100MG	N 205122	003	Mar 11, 2014		Apr CDFR
		150MG	N 205122	004	Mar 11, 2014		Apr CDFR
	+	200MG	N 205122	005	Mar 11, 2014		Apr CDFR

	TABLET; ORAL							
	TOPIRAMATE							
	@ WATSON LABS	25MG		A077643	001	Mar 27, 2009	May	DISC
	@	50MG		A077643	002	Mar 27, 2009	May	DISC
	@	100MG		A077643	003	Mar 27, 2009	May	DISC
	@	200MG		A077643	004	Mar 27, 2009	May	DISC
	<u>TOPOTECAN HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	TOPOTECAN HYDROCHLORIDE							
AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL		A201166	001	Aug 08, 2012	Apr	CAHN
	<u>TRAMADOL HYDROCHLORIDE</u>							
	TABLET; ORAL							
	TRAMADOL HYDROCHLORIDE							
AB	ALLIED PHARMA INC	50MG		A202075	001	Nov 28, 2011	Apr	CAHN
AB	AUROBINDO PHARMA LTD	50MG		A203494	001	Mar 31, 2014	Mar	NEWA
	@ WATSON LABS	50MG		A075962	001	Jun 24, 2002	May	DISC
	<u>TRANDOLAPRIL</u>							
	TABLET; ORAL							
	TRANDOLAPRIL							
>D>	AB	COREPHARMA	1MG	A077256	001	Jun 12, 2007	Jun	DISC
>A>	@		1MG	A077256	001	Jun 12, 2007	Jun	DISC
>D>	AB		2MG	A077256	002	Jun 12, 2007	Jun	DISC
>A>	@		2MG	A077256	002	Jun 12, 2007	Jun	DISC
>D>	AB		4MG	A077256	003	Jun 12, 2007	Jun	DISC
>A>	@		4MG	A077256	003	Jun 12, 2007	Jun	DISC
	<u>TRANEXAMIC ACID</u>							
	INJECTABLE; INJECTION							
	TRANEXAMIC ACID							
AP	ACIC FINE CHEMS	100MG/ML		A202436	001	Feb 11, 2014	Jan	NEWA
	TABLET; ORAL							
	TRANEXAMIC ACID							
AB	APOTEX INC	650 MG		A202286	001	Jan 27, 2014	Jan	NEWA
	<u>TRAVOPROST</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	IZBA							
	+ ALCON LABS INC	0.003%		N204822	001	May 15, 2014	May	NEWA
	TRAVOPROST							
	+ PAR PHARM	0.004%		A091340	001	Mar 01, 2013	Feb	CRLD
	<u>TRAZODONE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	TRAZODONE HYDROCHLORIDE							
	@ WATSON LABS	50MG		A070857	001	Oct 10, 1986	May	DISC
	@	100MG		A070858	001	Oct 10, 1986	May	DISC
>D>	<u>TREPROSTINIL</u>							
>D>	TABLET, EXTENDED RELEASE; ORAL							
>D>	ORENITRAM							
>D>	UNITED THERAP	0.125MG		N203496	001	Dec 20, 2013	Jun	CAIN
>D>		0.25MG		N203496	002	Dec 20, 2013	Jun	CAIN
>D>		1MG		N203496	003	Dec 20, 2013	Jun	CAIN
>D>	+	2.5MG		N203496	004	Dec 20, 2013	Jun	CAIN
>A>	<u>TREPROSTINIL DIOLAMINE</u>							
>A>	TABLET, EXTENDED RELEASE; ORAL							
>A>	ORENITRAM							
>A>	UNITED THERAP	EQ 0.125MG BASE		N203496	001	Dec 20, 2013	Jun	CAIN
>A>		EQ 0.25MG BASE		N203496	002	Dec 20, 2013	Jun	CAIN
>A>		EQ 1MG BASE		N203496	003	Dec 20, 2013	Jun	CAIN
>A>	+	EQ 2.5MG BASE		N203496	004	Dec 20, 2013	Jun	CAIN

TRETINOIN

GEL; TOPICAL

RETIN-A-MICRO

+ VALEANT INTL 0.08% N020475 003 Jan 28, 2014 Jan NEWA

SOLUTION; TOPICAL

RETIN-A

+ VALEANT INTL 0.05% N016921 001 Feb CTEC

TRETINOIN

@ WOCKHARDT 0.05% A075260 001 Jan 25, 1999 Feb DISC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

APOTHECON 10MG/ML N012041 001 May CTEC

KENALOG-40

+ APOTHECON 40MG/ML N014901 001 May CTEC

TRIAMCINOLONE ACETONIDE

@ SANDOZ 10MG/ML A090166 001 May 27, 2009 May DISC

@ SANDOZ CANADA INC 40MG/ML A090164 001 Jun 01, 2009 May DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

@ TARO 0.1% A089129 001 Aug 14, 1986 Mar DISC

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ WATSON LABS 0.125MG A074445 001 Oct 20, 1995 May DISC

@ 0.25MG A074445 002 Oct 20, 1995 May DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

@ WATSON LABS 2MG A040184 001 Feb 06, 1998 May DISC

@ 5MG A040184 002 Feb 06, 1998 May DISC

TRIMETHOENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

AP + PAR STERILE PRODUCTS 100MG/ML N017530 001 May CAHN

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND EQ 62.5MCG BASE/INH N205382 001 Apr 30, 2014 Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+ GLAXOSMITHKLINE EQ 0.0625MG BASE/INH; EQ 0.025MG N203975 001 Dec 18, 2013 Apr CAHN
BASE/INHUREA C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

@ OTSUKA AMERICA EQ 75MG /POUCH N020586 002 May 10, 2001 May DISC

URSODIOL

TABLET; ORAL

URSO 250

AB FOREST LABS INC 250MG N020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

AB + FOREST LABS INC 500MG N020675 002 Jul 21, 2004 Apr CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB APOTEX INC EQ 1GM BASE A090500 002 Apr 04, 2014 Mar NEWA

AB EQ 500MG BASE A090500 001 Apr 04, 2014 Mar NEWA

AB CIPLA LTD EQ 1GM BASE A077135 002 May 24, 2010 Jan CAHN

AB EQ 500MG BASE A077135 001 May 24, 2010 Jan CAHN

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	WATSON LABS INC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr	CAHN
AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr	CAHN

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA	ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

VALSARTAN

TABLET;ORAL

DIOVAN

>D>	NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun	CFTG
>A>	AB	40MG	N021283	004	Aug 14, 2002	Jun	CFTG
>D>		80MG	N021283	001	Jul 18, 2001	Jun	CFTG
>A>	AB	80MG	N021283	001	Jul 18, 2001	Jun	CFTG
>D>		160MG	N021283	002	Jul 18, 2001	Jun	CFTG
>A>	AB	160MG	N021283	002	Jul 18, 2001	Jun	CFTG
>D>	+	320MG	N021283	003	Jul 18, 2001	Jun	CFTG
>A>	AB	320MG	N021283	003	Jul 18, 2001	Jun	CFTG
>A>	VALSARTAN						
>A>	OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun	NEWA
>A>	AB	80MG	A077492	002	Jun 26, 2014	Jun	NEWA
>A>	AB	160MG	A077492	003	Jun 26, 2014	Jun	NEWA
>A>	AB	320MG	A077492	004	Jun 26, 2014	Jun	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOCIN HYDROCHLORIDE

AB	SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	May	CAHN
AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	May	CAHN

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb	CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May	CAHN
AP		EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May	CAHN

VASOPRESSIN

SOLUTION;IV (INFUSION)

VASOSTRICT

+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	NEWA
---	----------------------	-------------------------	---------	-----	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

@	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995	May	DISC
@		20MG/VIAL	A074334	002	Aug 31, 1995	May	DISC

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB	MYLAN	80MG	A071483	002	Feb 15, 1989	Apr	CMS1
@	WATSON LABS	40MG	A072923	001	Jun 29, 1993	May	DISC
@		80MG	A070855	001	Sep 24, 1986	May	DISC
@		80MG	A071366	001	Oct 01, 1986	May	DISC
@		120MG	A070856	001	Sep 24, 1986	May	DISC
@		120MG	A071367	001	Oct 01, 1986	May	DISC

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

>A>	AB	ANI PHARMS INC	120MG	A090529	001	Dec 30, 2011	Jun	CAHN
>A>	AB		180MG	A090529	002	Dec 30, 2011	Jun	CAHN
>A>	AB		240MG	A090529	003	Dec 30, 2011	Jun	CAHN
>D>	AB	CARACO	120MG	A090529	001	Dec 30, 2011	Jun	CAHN
>D>	AB		180MG	A090529	002	Dec 30, 2011	Jun	CAHN
>D>	AB		240MG	A090529	003	Dec 30, 2011	Jun	CAHN

VORAPAXAR SULFATETABLET; ORAL
ZONTIVITY

>A>	+	MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014	Jun CPOT
>D>	+		EQ 2.5MG BASE	N204886	001	May 08, 2014	Jun CPOT
	+		EQ 2.5MG BASE	N204886	001	May 08, 2014	May NEWA

WARFARIN SODIUMINJECTABLE; INJECTION
COUMADIN

	@	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar DISC
--	---	----------------------	----------	---------	-----	--------------	----------

TABLET; ORAL
COUMADIN

AB		BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr CMFD
	@		1MG	N009218	022	Mar 01, 1990	Mar DISC
AB			2MG	N009218	013		Apr CMFD
	@		2MG	N009218	013		Mar DISC
AB			2.5MG	N009218	018		Apr CMFD
	@		2.5MG	N009218	018		Mar DISC
AB			3MG	N009218	025	Nov 18, 1996	Apr CMFD
	@		3MG	N009218	025	Nov 18, 1996	Mar DISC
AB			4MG	N009218	023	Aug 24, 1993	Apr CMFD
	@		4MG	N009218	023	Aug 24, 1993	Mar DISC
AB			5MG	N009218	007		Apr CMFD
AB			6MG	N009218	026	Nov 18, 1996	Apr CMFD
	@		6MG	N009218	026	Nov 18, 1996	Mar DISC
AB			7.5MG	N009218	016		Apr CMFD
	@		7.5MG	N009218	016		Mar DISC
AB	+		10MG	N009218	005		Apr CMFD

ZICONOTIDE ACETATEINJECTABLE; INTRATHECAL
PRIALT

	@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb CAIN
--	---	------------------	------------------------	---------	-----	--------------	----------

ZIDOVUDINEINJECTABLE; INJECTION
ZIDOVUDINE

	@	LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar DISC
--	---	------------------	---------	---------	-----	--------------	----------

ZILEUTONTABLET; ORAL
ZYFLO

	@	CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr CAHN
	+		600MG	N020471	003	Dec 09, 1996	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
ZYFLO CR

	+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr CAHN
--	---	----------------	-------	---------	-----	--------------	----------

ZOLEDRONIC ACIDINJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May NEWA
----	--	-----------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTANTABLET; ORAL
ZOLMITRIPTAN

AB		INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar NEWA
AB			5MG	A204284	002	Apr 09, 2014	Mar NEWA
AB		TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb NEWA
AB			5MG	A090861	002	Mar 04, 2014	Feb NEWA

ZOLPIDEM TARTRATETABLET; ORAL
ZOLPIDEM TARTRATE

	@	VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr CAHN
	@		10MG	A076062	002	Apr 23, 2007	Apr CAHN
	@	WATSON LABS	5MG	A077773	001	Apr 23, 2007	May DISC
	@		10MG	A077773	002	Apr 23, 2007	May DISC

ZONISAMIDE

CAPSULE; ORAL		ZONISAMIDE							
AB	ANI PHARMS INC	25MG	A 077639	001	Dec 22, 2005	Jan	CAHN		
	@	25MG	A 077641	003	Dec 22, 2005	Jan	CAHN		
AB		50MG	A 077639	002	Dec 22, 2005	Jan	CAHN		
	@	50MG	A 077641	002	Dec 22, 2005	Jan	CAHN		
AB		100MG	A 077639	003	Dec 22, 2005	Jan	CAHN		
	@	100MG	A 077641	001	Dec 22, 2005	Jan	CAHN		
	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Feb	DISC		
	@	50MG	A 077644	002	Dec 22, 2005	Feb	DISC		
	@	100MG	A 077644	003	Dec 22, 2005	Feb	DISC		

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
 DRIXORAL PLUS
 @ SCHERING PLOUGH 500MG;3MG;60MG N019453 001 May 22, 1987 Feb DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL
 CETIRIZINE HYDROCHLORIDE ALLERGY
 IPCA LABS LTD 5MG A202277 002 Mar 11, 2014 Feb NEWA
 10MG A202277 004 Mar 11, 2014 Feb NEWA
 CETIRIZINE HYDROCHLORIDE HIVES
 IPCA LABS LTD 5MG A202277 001 Mar 11, 2014 Feb NEWA
 10MG A202277 003 Mar 11, 2014 Feb NEWA
 TABLET, CHEWABLE;ORAL
 CETIRIZINE HYDROCHLORIDE ALLERGY
 @ CARACO 5MG A077631 004 Jan 11, 2008 Feb DISC
 @ 10MG A077631 003 Jan 11, 2008 Feb DISC
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF
 @ CARACO 5MG A077631 001 Jan 11, 2008 Feb DISC
 @ 10MG A077631 002 Jan 11, 2008 Feb DISC

CIMETIDINE

TABLET;ORAL
 CIMETIDINE
 @ WATSON LABS 200MG A075425 001 Jul 29, 1999 May DISC

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE
 + AVANTHI INC 6MG;120MG A078648 001 Feb 27, 2013 Jan CRLD
 DISOPHROL
 @ SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982 Jan DISC
 DRIXORAL
 @ SCHERING PLOUGH 6MG;120MG N013483 003 Sep 13, 1982 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL
 ALEVE PM
 + BAYER HLTHCARE 25MG;220MG N205352 001 Jan 17, 2014 Jan NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
 NEXIUM
 ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014 Apr CMS2
 NEXIUM 24HR
 + ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014 Apr CTNA

FAMOTIDINE

TABLET;ORAL
 FAMOTIDINE
 @ WATSON LABS 10MG A075404 001 Nov 28, 2001 May DISC

IBUPROFEN

SUSPENSION;ORAL
 CHILDREN'S ELIXSURE
 MOBERG PHARMA NORTH 100MG/5ML N021604 001 Jan 07, 2004 May CAHN
 TABLET;ORAL
 IBUPROFEN
 ANNEAL PHARMS 200MG A079233 001 Mar 18, 2014 Mar NEWA
 @ WATSON LABS 200MG A070435 001 Mar 05, 1986 May DISC

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL
 >A> IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
 >A> PERRIGO R AND D 200MG;10MG A203200 001 Jul 03, 2014 Jun NEWA

LEVONORGESTRELTABLET;ORAL
FALLBACK SOLO
LUPIN LTD

>A>

1.5MG

A201446 001 Jun 19, 2014 Jun NEWA

MINOXIDILAEROSOL, FOAM;TOPICAL
WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2014

NO JUNE 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	>A> 8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001 >A>	8747896	Jun 03, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8709392	Sep 15, 2026	DP U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8645160	Jun 18, 2029	U-1485			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		>A> M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001					>A> M-137	Jun 09, 2017
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8722679	Oct 19, 2024	DP			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8722679	Oct 19, 2024	DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	>A> 5849911	Jun 20, 2017	DS DP U-167		>A> NP	Jun 02, 2017
	>A> 6087383	Dec 21, 2018	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	>A> 5686104	Nov 11, 2014	DP U-1400			
	>A> 5686104*PED	May 11, 2015				
	>A> 5969156	Jul 08, 2016	DS			
	>A> 5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	>A> 5686104	Nov 11, 2014	DP U-1400			
	>A> 5686104*PED	May 11, 2015				
	>A> 5969156	Jul 08, 2016	DS			
	>A> 5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	>A> 5686104	Nov 11, 2014	DP U-1400			
	>A> 5686104*PED	May 11, 2015				
	>A> 5969156	Jul 08, 2016	DS			
	>A> 5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	>A> 5686104	Nov 11, 2014	DP U-1400			
	>A> 5686104*PED	May 11, 2015				
	>A> 5969156	Jul 08, 2016	DS			
	>A> 5969156*PED	Jan 08, 2017				
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001					NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
	>A> 8758733	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					ODE	Jun 20, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	>A> 8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	>A> 8754131	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	>A> 6159498	Oct 18, 2016	DP		>A> NP	Jun 06, 2017
	>A> 7579019	Jan 22, 2020	U-1521			
	>A> 8147866	Jul 23, 2027	DP U-1521			
	>A> 8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	>A> 6159498	Oct 18, 2016	DP		>A> NP	Jun 06, 2017
	>A> 7579019	Jan 22, 2020	U-1521			
	>A> 8147866	Jul 23, 2027	DP U-1521			
	>A> 8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	>A> 6159498	Oct 18, 2016	DP		>A> NP	Jun 06, 2017
	>A> 7579019	Jan 22, 2020	U-1521			
	>A> 8147866	Jul 23, 2027	DP U-1521			
	>A> 8703177	Aug 20, 2032	DP			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CERTINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
	8716264*PED	Jul 13, 2024				
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678	Jan 08, 2017
					ODE	Jan 09, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	>A> 6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	>A> 7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	>A> 7119061	Nov 14, 2023	DP			
	>A> 8143212	Nov 14, 2023	U-1517			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8663685	Jan 18, 2025	U-1030			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	>A> 8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	>A> 8277780	Sep 01, 2028	DP U-1408			
	>A> 8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001					>A> I-686	Jun 29, 2017
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	>A> 8759393	Oct 29, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	>A> 8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 03, 2024	DP U-257			
	8716264*PED	Jul 03, 2024				
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	>A> 7214506	Oct 05, 2021	U-281		>A> NCE	Jun 06, 2019
	>A> 8039494	Jul 08, 2030	U-281			
	>A> 8486978	Oct 24, 2030	DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
	8716264*PED	Jul 13, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8716264	Jan 13, 2024	DP U-257			
	8716264*PED	Jul 13, 2024				
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	>A> 6143771	May 27, 2015	DP U-643			
	>A> 6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	>A> 6143771	May 27, 2015	DP U-643			
	>A> 6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	>A> 6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Dec 26, 2028	DP			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	>A> 8728441	Mar 26, 2019	U-1514			
	>A> 8753611	Mar 26, 2019	U-1514			
	>A> 8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	>A> 8728441	Mar 26, 2019	U-1514			
	>A> 8753611	Mar 26, 2019	U-1514			
	>A> 8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	>A> 8728441	Mar 26, 2019	U-1514			
	>A> 8753611	Mar 26, 2019	U-1514			
	>A> 8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	>A> 8728441	Mar 26, 2019	U-1514			
	>A> 8753611	Mar 26, 2019	U-1514			
	>A> 8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	>A> 8728441	Mar 26, 2019	U-1514			
	>A> 8753611	Mar 26, 2019	U-1514			
	>A> 8765100	Mar 26, 2019	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEO</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	>A> 8347879	Jul 15, 2028	DP			
	>A> 8752543	Apr 05, 2026	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 8746242	Oct 10, 2030	DP		NP	May 10, 2016
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					>A> I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					>A> I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					>A> I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					>A> I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					>A> I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					>A> I-688 >A> NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014		U-441		
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030		U-441		
	8367605	May 24, 2014	DS			
	8399413	Sep 06, 2030		U-441		
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030		U-1383		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP	U-1087		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026		U-1456	I-680	Feb 12, 2017
	8476284	Dec 28, 2026		U-1491	ODE	Feb 12, 2021
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8754090	Jun 03, 2031		U-1456		
	>A> 8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029		U-981		
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	>A> 5648333	Jul 15, 2015	DS DP	U-1187		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8716271	Dec 18, 2026	U-1440			
	>A> 8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8716271	Dec 18, 2026	U-1440			
	>A> 8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	>A> 8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	>A> 8586633	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	>A> 8741929	Mar 08, 2028	U-1414			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	>A> 8759401	Jul 24, 2026	DP			U-1523
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	>A> 8748573	Jun 20, 2031				U-1515
	>A> 8748573	Jun 20, 2031				U-1516
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	>A> 8748573	Jun 20, 2031				U-1515
	>A> 8748573	Jun 20, 2031				U-1516
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027				U-1503
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027				U-1503
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027				U-1503
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027				U-1503
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025				U-1316
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025				U-1316
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025				U-1316
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	>A> 8691878	Aug 25, 2024				U-1513
	>A> 8691878*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	>A> 8691878	Aug 25, 2024				U-1513
	>A> 8691878*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS	DP		
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021				DP
	7537009	Oct 28, 2024				DP
	8074644	Jul 25, 2022				DP
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	>A> 8748481	Sep 01, 2025				U-1519
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	>A> 8748481	Sep 01, 2025				U-1520
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026				DP
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026				DP

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS			
	8729085	May 26, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
	>A> 8039009	Mar 24, 2029	U-539			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-539			
	>A> 8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
	>A> 8039009	Mar 24, 2029	U-539			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-539			
	>A> 8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
	>A> 8039009	Mar 24, 2029	U-539			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-539			
	>A> 8362085*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	>A> 5061703	Apr 11, 2015	U-539			
	>A> 5061703*PED	Oct 11, 2015				
	>A> 8039009	Mar 24, 2029	U-539			
	>A> 8039009*PED	Sep 24, 2029				
	>A> 8168209	Nov 22, 2025	DP			
	>A> 8168209*PED	May 22, 2026				
	>A> 8173708	Nov 22, 2025	U-539			
	>A> 8173708*PED	May 22, 2026				
	>A> 8283379	Nov 22, 2025	U-539			
	>A> 8283379*PED	May 22, 2026				
	>A> 8329752	Nov 22, 2025	DP			
	>A> 8329752*PED	May 22, 2026				
	>A> 8362085	Nov 22, 2025	U-539			
	>A> 8362085*PED	May 22, 2026				
	>A> 8598233	Nov 22, 2025	DP			
	>A> 8598233*PED	May 22, 2026				
<u>MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001 >A>	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002 >A>	RE44872	Dec 18, 2023	U-1527			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8223610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CQ</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-132 PED	Dec 21, 2013 Jun 21, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	>A> 5840757	Nov 24, 2015	DP		>A> NP	Oct 03, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	>A> 8754108	Nov 17, 2021	DP			
	>A> 8754108*PED	May 17, 2022				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	>A> 8734833	May 26, 2020	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	>A> 8735428	May 15, 2023	U-1360			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	>A> 8735428	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	>A> 8735428	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	>A> 8735428	May 15, 2023	U-1360			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026	DP			
	>A> 8741904	Feb 27, 2026	DS U-1526			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
	>A> 8741904	Feb 27, 2026	DS U-1526			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	>A> 8691878	Aug 25, 2024	U-688			
	>A> 8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8722693	Jun 12, 2028	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156			
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	>A> 8741926	Jul 28, 2026	DS	U-1467		
	>A> 8754106	Jul 28, 2026	DS	U-1467		
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022		U-1110		
	>A> 8772306	Mar 15, 2033		U-1525		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP	U-1470		
	8633309	Mar 26, 2029	DS DP	U-1470		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022		DP		
	8684969	Oct 20, 2025		DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022		DP		
	8684969	Oct 20, 2025		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001 >A>	8741620	Feb 24, 2024	DS DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE ODE	Jan 31, 2019 Jan 31, 2021
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					>A> I-687	Jun 13, 2017
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001 >A>	7816379	Feb 23, 2028	DS DP U-282		>A> NCE	Jun 20, 2019
	>A> 8420676	Feb 23, 2028	DS DP U-282		>A> GAIN	Jun 20, 2024
	>A> 8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001 >A>	7816379	Feb 23, 2028	DS DP U-282		>A> NCE	Jun 20, 2019
	>A> 8420676	Feb 23, 2028	DS DP U-282		>A> GAIN	Jun 20, 2024
	>A> 8426389	Dec 31, 2030	DS DP U-282			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001 >A>	8729057	Oct 12, 2026	DP			
	>A> 8741881	Oct 12, 2026	U-1103			
	>A> 8754070	Oct 12, 2026	DP			
	>A> 8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002 >A>	8729057	Oct 12, 2026	DP			
	>A> 8741881	Oct 12, 2026	U-1103			
	>A> 8754070	Oct 12, 2026	DP			
	>A> 8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003 >A>	8729057	Oct 12, 2026	DP			
	>A> 8741881	Oct 12, 2026	U-1103			
	>A> 8754070	Oct 12, 2026	DP			
	>A> 8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002					>A> NP	Jun 04, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - VOGELXO</u>						
N 204399	003				>A> NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488	001	>A> 8574622	Feb 04, 2024	DP	NP	May 28, 2017
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219	001	7718640	Mar 14, 2027	DP	NP	Mar 05, 2017
		8338395	Feb 27, 2026	U-1500		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	001	8626531	Oct 23, 2020		U-1465	
<u>THALIDOMIDE - THALOMID</u>						
N 020785	002	8626531	Oct 23, 2020		U-1465	
<u>THALIDOMIDE - THALOMID</u>						
N 020785	003	8626531	Oct 23, 2020		U-1465	
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	8626531	Oct 23, 2020		U-1465	
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516	001	6645963	Nov 16, 2018	DP		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001				M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001	5753677	May 19, 2020		U-978	
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002	5753677	May 19, 2020		U-978	
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003	5753677	May 19, 2020		U-978	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	8663683	Nov 16, 2027	DP	U-106	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	8663683	Nov 16, 2027	DP	U-106	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	8663683	Nov 16, 2027	DP	U-106	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	8663683	Nov 16, 2027	DP	U-106	
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001	8652527	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002	8652527	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003	8652527	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004	8652527	Mar 19, 2033	DP		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005	8652527	Mar 19, 2033	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001				I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002				I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003				I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAVOPROST - IZBA</u>						
N 204822	001	8722735	Oct 10, 2029	DP	NP	May 15, 2017
	>A>	8754123	May 19, 2029	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001 >A>	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002 >A>	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003 >A>	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004 >A>	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001 >A>	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	>A> 8746242	Oct 10, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8201556	Feb 05, 2029	DP		NP	Dec 18, 2016
	>A> 8746242	Oct 10, 2030	DP			
	>A> RE44874	Mar 23, 2023	DS DP	U-1476		
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					>A> PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					>A> PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					>A> PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					>A> PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	>A> 8765680	Oct 01, 2024	U-48			
	>A> 8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	>A> 8765680	Oct 01, 2024	U-48			
	>A> 8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	>A> 8765680	Oct 01, 2024	U-48			
	>A> 8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	>A> 8765680	Oct 01, 2024	U-48			
	>A> 8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>